Page last updated: 2024-12-06

pregnanolone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pregnanolone is a naturally occurring neurosteroid that is synthesized in the brain from progesterone. It has been shown to have anxiolytic, anticonvulsant, and sedative effects. Pregnanolone is also a potent positive allosteric modulator of the GABAu003csubu003eAu003c/subu003e receptor, a major inhibitory neurotransmitter receptor in the brain. The importance of pregnanolone lies in its potential therapeutic applications in conditions like anxiety, epilepsy, and insomnia. Research into pregnanolone focuses on its mechanism of action, its therapeutic potential, and its role in neuropsychiatric disorders. Pregnanolone has been the subject of much research due to its potential for treating a wide range of neurological and psychiatric disorders. Some studies have shown that pregnanolone can be effective in treating anxiety, epilepsy, and insomnia, while others have suggested that it may also play a role in the development of depression.'

Pregnanolone: A pregnane found in the urine of pregnant women and sows. It has anesthetic, hypnotic, and sedative properties. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3alpha-hydroxy-5beta-pregnan-20-one : The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID31402
CHEMBL ID210952
CHEBI ID1712
SCHEMBL ID56664
MeSH IDM0017509

Synonyms (102)

Synonym
eltanolona
(3alpha,5beta)-3-hydroxypregnan-20-one
CHEBI:1712 ,
eltanolonum
3alpha-hydroxy-5beta-pregnane-20-one
pregnan-20-one, 3-hydroxy-, (3.alpha.,5.beta.)-
pregnan-3alpha-ol-20-one
eltanolone
skf 6455
5.beta.-pregnan-20-one, 3.alpha.-hydroxy-
pregnan-3.alpha.-ol-20-one
nsc-82867
pregnan-20-one, (3.alpha.,5.beta.)-
3.alpha.-hydroxy-5.beta.-tetrahydroprogesterone
3.alpha.,5.beta.-epimeric pregnanolone
3.alpha.-hydroxy-5.beta.-pregnan-20-one
pregnanolone ii
nsc82867
mls002694512 ,
3alpha-hydroxy-5beta-tetrahydroprogesterone
eltanolone [inn]
3 alpha-hydroxy-5 alpha-pregnan-20-one
pregnan-20-one, 3-hydroxy-, (3alpha,5beta)-
allopregnan-3 beta-ol-20-one
brn 4785659
3-alpha-hydroxy-5-beta-pregnan-20-one
nsc 82867
pregnanolone, (3alpha,5alpha)-isomer
pregnanolone, (3alpha,5beta)-isomer
5-beta-pregnan-20-one, 3-alpha-hydroxy-
eltanolonum [inn-latin]
3 alpha, 5 beta-tetrahydroprogesterone
5beta-pregnan-20-one, 3alpha-hydroxy-
eltanolona [inn-spanish]
pregnanolone, (3beta, 5alpha)-isomer
3 alpha-hydroxy-5 beta-pregnan-20-one
3alpha,5beta-epimeric pregnanolone
wln: l e5 b666tj a1 e1 fv1 oq
128-20-1
pregnanolone
C05480
3alpha-hydroxy-5beta-pregnan-20-one
5beta-pregnan-3alpha-ol-20-one
beta-ol-20-one, allopregnan-3
pregnanolone, (3beta)-isomer
pregnanolone, (3beta, 5alpha, 17alpha)-isomer
beta-pregnan-20-one, 3 alpha-hydroxy-5
pregnanolone, (3beta, 5beta)-isomer
pregnanolone, (3alpha)-isomer
alpha-pregnan-20-one, 3 alpha-hydroxy-5
3 hydroxypregnan 20 one
pregnanolone, (3beta, 5beta, 17alpha)-isomer
alpha-hydroxy-5 alpha-pregnan-20-one, 3
3 alpha hydroxy 5 beta pregnan 20 one
pregnanolone, (3beta, 5beta,14beta)-isomer
3beta hydroxy 5alpha pregnan 20 one
pregnanolone, (3beta, 5alpha, 8alpha, 17beta)-isomer
alpha-hydroxy-5 beta-pregnan-20-one, 3
allopregnan 3 beta ol 20 one
3 alpha hydroxy 5 alpha pregnan 20 one
pregnanolone, (5alpha)-isomer
pregnanolone, (3alpha, 5beta, 17-alpha)-isomer
3 alpha, 5 beta tetrahydroprogesterone
pregnan 3alpha ol 20 one
kabi 2213
skf-6455
CHEMBL210952
kabi-2213
1-[(3r,5r,8r,9s,10s,13s,14s,17s)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone
LMST02030175
dtxcid101474386
dtxsid1046342 ,
tox21_112042
cas-128-20-1
unii-bxo86p3xxw
bxo86p3xxw ,
SCHEMBL56664
pregnan-3.alpha.-ol-20-one [mi]
eltanolone [mart.]
(3?,5?)-3-hydroxy-pregnan-20-one
3.alpha.,5.beta.-pregnanolone
5.beta.-pregnan-3.alpha.-ol-20-one
3-hydroxypregnan-20-one, (3.alpha.,5.beta.)-
J-005571
pregnan-3a-ol-20-one
p9n ,
pregnan-20-one, 3-hydroxy-, (3a,5b)-
3a-hydroxy-5b-pregnan-20-one
(3a,5b)-3-hydroxypregnan-20-one
DB12308
1-((3r,5r,8r,9s,10s,13s,14s,17s)-3-hydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)ethan-1-one
110350-90-8
Q18344323
1-((3r,5r,8r,9s,10s,13s,14s,17s)-3-hydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)ethanone
5?-pregnan-3?-ol-20-one
gtpl11534
3alpha,5beta-thp
3alpha,5beta-tetrahydroprogesterone
(3alpha,5beta)-3-hydroxy-pregnan-20-one
5 beta -pregnan-3 alpha -ol-20-one
skf6455
kabi2213

Research Excerpts

Overview

Allopregnanolone (allo) is a physiological regulator of neuronal activity that treats multiple neurological disorders. It is a neurosteroid synthesized in the central nervous system independently of steroidogenic glands; it influences sexual behavior and anxiety.

ExcerptReferenceRelevance
"Allopregnanolone (allo) is a physiological regulator of neuronal activity that treats multiple neurological disorders. "( Allopregnanolone suppresses glioblastoma survival through decreasing DPYSL3 and S100A11 expression.
Feng, YH; Hsu, SP; Hsu, TI; Kao, TJ; Ko, CY; Lim, SW; Lin, HY; Wang, SA, 2022
)
1.84
"Allopregnanolone (ALLO) is a neuroactive steroid hormone that plays a crucial role in the aetiology of reproductive mood disorders."( Validation of a Commercial Enzyme-Linked Immunosorbent Assay for Allopregnanolone in the Saliva of Healthy Pregnant Women.
Ehlert, U; Grötsch, MK; Hettich, T; Wietor, DM, 2022
)
1.44
"Allopregnanolone acts as a positive allosteric modulator preferentially on δ subunit-containing GABA"( Impaired Endogenous Neurosteroid Signaling Contributes to Behavioral Deficits Associated With Chronic Stress.
Antonoudiou, P; Barros, L; Dargan, T; DiLeo, A; Evans-Strong, A; Gabby, J; Howard, S; Kong, D; Maguire, JL; Paracha, R; Sánchez, EJ; Walton, NL; Weiss, GL, 2023
)
1.39
"Allopregnanolone (AP) is a neurosteroid synthesized in the brain and a positive allosteric modulator of γ-aminobutyric acid (GABA) type A receptors. "( Drugs possessing aryloxypropanamine pharmacophore, duloxetine, dapoxetine and propranolol, increase allopregnanolone in rat brain: Possible involvement of allopregnanolone in their central nervous system effects.
Higashi, T; Hirakawa, A; Makino, K; Nishimoto-Kusunose, S; Takahashi, H; Tanaka, A; Yoshizawa, K, 2023
)
1.68
"Allopregnanolone is a kind of neuroactive steroid or neurosteroid in the central nervous system that acts as an endogenenous GABA"( Research Trends and Hot Spots of Allopregnanolone Research in the Last 20 Years: A Bibliometric Analysis.
Feng, S; Guo, K; Mao, M; Wang, X; Xu, S; Zhang, S; Zhao, L, 2023
)
1.74
"Allopregnanolone is a metabolite from progesterone and a positive modulator of the GABA"( Treatment of premenstrual dysphoric disorder with the GABA
Andréen, L; Bäckström, T; Bixo, M; Ehrenborg, A; Ekberg, K; Hirschberg, AL; Jonasson, AF; Poromaa, IS; Timby, E; Wulff, M, 2017
)
1.01
"Allopregnanolone is a neurosteroid synthesized in the central nervous system independently of steroidogenic glands; it influences sexual behavior and anxiety. "( Allopregnanolone alters follicular and luteal dynamics during the estrous cycle.
Asensio, JA; Cáceres, ARR; Laconi, MR; Parborell, F; Pelegrina, LT; Sanhueza, MLÁ; Scotti, L, 2018
)
1.6
"Allopregnanolone is a neurosteroid implicated in mood disorders such as depression and anxiety. "( Hemisphere-dependent Changes in mRNA Expression of GABA
Almeida, FB; Barros, HMT; Gomez, R; Nin, MS, 2019
)
1.07
"Allopregnanolone (ALLO) is a neurosteroid produced in the brain, but so far, no study has explored its link with itching. "( Brain allopregnanolone induces marked scratching behaviour in diet-induced atopic dermatitis mouse model.
Asano, E; Fujii, M; Nabe, T; Nakayama, T; Ohgami, S; Ohya, S; Toda, T, 2019
)
1.47
"Allopregnanolone (Allop) is a metabolite of progesterone and a potent modulator of GABAA-ergic currents whose defects are seen in RTT."( Time-dependent modulation of GABA(A)-ergic synaptic transmission by allopregnanolone in locus coeruleus neurons of Mecp2-null mice.
Jiang, C; Jin, X; Zhong, W, 2013
)
1.1
"Allopregnanolone is a neurosteroid involved in depression, memory, social, and sexual behavior. "( Decreased allopregnanolone induced by hormonal contraceptives is associated with a reduction in social behavior and sexual motivation in female rats.
Berretti, R; Concas, A; Locci, A; Porcu, P; Santoru, F, 2014
)
1.32
"Allopregnanolone (Allop) is a NS that exerts its effect mainly through the modulation of the GABAA receptor (GABAAR)."( Neonatal allopregnanolone or finasteride administration modifies hippocampal K(+) Cl(-) co-transporter expression during early development in male rats.
Casas, C; Darbra, S; Llidó, A; Mòdol, L; Navarro, X; Pallarès, M, 2014
)
1.25
"Allopregnanolone is a neurosteroid synthesized from progesterone in brain. "( Allopregnanolone and its precursor progesterone do not reduce injury after experimental stroke in hypertensive rats - role of postoperative temperature regulation?
Calford, MB; McLeod, DD; Pepperall, D; Spratt, NJ; Tomkins, AJ, 2014
)
1.52
"Allopregnanolone (ALLO) is an endogenous neuroactive steroid thought to alter the reinforcement value of alcohol (ethanol) due to its actions as a positive modulator of the GABAA receptor (GABAAR). "( Effect of nucleus accumbens shell infusions of ganaxolone or gaboxadol on ethanol consumption in mice.
Finn, DA; Ford, MM; Phillips, TJ; Ramaker, MJ; Strong-Kaufman, MN, 2015
)
0.98
"Allopregnanolone is a neurosteroid and powerful modulator of neuronal excitability. "( Neurosteroids are endogenous neuroprotectants in an ex vivo glaucoma model.
Ishikawa, M; Izumi, Y; Yoshitomi, T; Zorumski, CF, 2014
)
0.96
"Allopregnanolone (AP) is an endogenous neurosteroid. "( Isoallopregnanolone antagonize allopregnanolone-induced effects on saccadic eye velocity and self-reported sedation in humans.
Bäckström, T; Bengtsson, SK; Bixo, M; Hedström, H; Jonsson, B; Nyberg, S; Zingmark, E, 2015
)
1.43
"Allopregnanolone is a modulator of the GABAA receptor, enhancing the effect of γ-aminobutyric acid (GABA)."( Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study.
Bäckström, T; Bixo, M; Nyberg, S; Stenlund, H; Timby, E; Wihlbäck, AN, 2016
)
1.15
"Allopregnanolone is an endogenous neurosteroid reduced in chronic stress, and when administered, decreases anxiety by positive allosteric modulation of GABAA receptors."( Positive allosteric modulation of GABAA receptors attenuates high blood pressure in Schlager hypertensive mice.
Davern, PJ; Evans, RG; Head, GA; Jackson, KL; Johns, EM; Marques, FZ; Stevenson, ER, 2017
)
0.94
"Allopregnanolone is an endogenous neuroactive steroid that, through its binding to the gamma-aminobutyric acid (GABA) A receptor, has GABA-active properties. "( Allopregnanolone impairs episodic memory in healthy women.
Bäckström, T; Kask, K; Nilsson, LG; Sundström-Poromaa, I, 2008
)
1.46
"Allopregnanolone (ALLO) is a physiologically relevant neurosteroid modulator of GABA(A) receptors, and it exhibits a psychopharmacological profile that closely resembles the post-ingestive effects of ethanol. "( Inhibition of 5alpha-reduced steroid biosynthesis impedes acquisition of ethanol drinking in male C57BL/6J mice.
Finn, DA; Ford, MM; Fretwell, A; Strong, MN; Tanchuck, M; Yoneyama, N, 2008
)
0.9
"Allopregnanolone is an endogenous neuroactive steroid which, through the binding to the GABA(A) receptor, enhances inhibitory neurotransmission and exerts anxiolytic, sedative and antiepileptic effects. "( Allopregnanolone has no effect on startle response and prepulse inhibition of startle response in patients with premenstrual dysphoric disorder or healthy controls.
Bäckström, T; Kask, K; Lundgren, P; Sundström Poromaa, I, 2009
)
1.47
"Pregnanolone sulfate (PAS) is an endogenous neurosteroid that inhibits NMDA receptors and is neuroprotective in vivo."( Pregnanolone sulfate promotes desensitization of activated NMDA receptors.
Kaur, N; Kussius, CL; Popescu, GK, 2009
)
2.52
"Allopregnanolone (ALLO) is a progesterone derivative that rapidly potentiates gamma-aminobutyric acid(A) (GABA(A)) receptor-mediated inhibition and modulates symptoms of ethanol withdrawal. "( Selected line difference in the effects of ethanol dependence and withdrawal on allopregnanolone levels and 5alpha-reductase enzyme activity and expression.
Crabbe, JC; Finn, DA; Ford, MM; Hashimoto, J; Long, SL; Roselli, CE; Tanchuck, MA; Wiren, KM, 2009
)
1.14
"Allopregnanolone is a 5α-reduced metabolite of progesterone with actions on γ-aminobutyric acid-A (GABAA) receptors that produce antidepressant-like effects. "( Allopregnanolone microinjected into the lateral septum or dorsal hippocampus reduces immobility in the forced swim test: participation of the GABAA receptor.
Contreras, CM; García-Ríos, RI; Rodríguez-Landa, JF, 2009
)
1.47
"Allopregnanolone (AlloP) is a neurosteroid that plays an important role during neural development. "( Alterations in neonatal neurosteroids affect exploration during adolescence and prepulse inhibition in adulthood.
Darbra, S; Pallarès, M, 2010
)
0.92
"Allopregnanolone (AP) is a circulating neuroactive steroid involved in modulation of behavioral activities whose serum levels are increased in obese children."( Circulating levels of allopregnanolone, a neuroactive steroid, and leptin during treatment with valproic acid in children with epilepsy.
Balestri, P; Barlocco, EG; Casarosa, E; Grosso, S; Luisi, S; Matera, M; Mostardini, R; Petraglia, F, 2011
)
1.15
"Allopregnanolone (ALLO) is a modulator of the GABA(A) receptor and has similar behavioral effects as ethanol."( Effect of acute ethanol and acute allopregnanolone on spatial memory in adolescent and adult rats.
Berry, RB; Chin, VS; Diaz-Granados, J; Kirk, RE; Matthews, DB; Van Skike, CE, 2011
)
1.12
"Allopregnanolone (ALLO) is a neurosteroid that has many functions in the brain, most notably neuroprotection and modulation of gamma-amino butyric acid (GABA) neurotransmission. "( Sex difference in sensitivity to allopregnanolone neuroprotection in mice correlates with effect on spontaneous inhibitory post synaptic currents.
Herson, PS; Kelley, MH; Kuroiwa, M; Taguchi, N, 2011
)
1.2
"Allopregnanolone is a potent positive modulator of γ-aminobutyric acid A (GABA(A)) receptor function."( Progesterone and allopregnanolone exacerbate hypoxic-ischemic brain injury in immature rats.
Ikeda, T; Kasahara, Y; Ohshima, M; Taguchi, A; Tsuji, M, 2012
)
1.18
"Allopregnanolone is an endogenous steroid, that positively modulates the GABA(A) receptor, and that has anti-apoptotic and anti-excitotoxic actions, reducing brain damage in adult animal models of brain injury."( Effect of maternal administration of allopregnanolone before birth asphyxia on neonatal hippocampal function in the spiny mouse.
Castillo-Melendez, M; Coleman, HA; Dickinson, H; Fleiss, B; Hirst, JJ; Parkington, HC; Walker, DW; Yawno, T, 2012
)
1.13
"Allopregnanolone (ALLO) is a potent positive modulator of γ-aminobutyric acidA receptors (GABAA Rs) that affects ethanol (EtOH) withdrawal. "( Local changes in neurosteroid levels in the substantia nigra reticulata and the ventral tegmental area alter chronic ethanol withdrawal severity in male withdrawal seizure-prone mice.
Cozzoli, DK; Crabbe, JC; Finn, DA; He, I; Kaufman, KR; Mark, GP; Snelling, C; Tanchuck, MA, 2013
)
0.95
"Allopregnanolone is an endogenously produced neuroactive steroid that acts at the GABA-A receptor."( Initial sensitivity, tolerance and cross-tolerance to allopregnanolone- and ethanol-induced hypothermia in selected mouse lines.
Crabbe, JC; Moyer, MR; Palmer, AA; Phillips, TJ, 2002
)
1.04
"Allopregnanolone is a neuroactive metabolite of progesterone and a barbiturate-like modulator of central gamma-aminobutyric acid receptors that modify a range of behaviors, including the stress response. "( Allopregnanolone levels and symptom improvement in severe premenstrual syndrome.
Freeman, EW; Frye, CA; Martin, PA; Rickels, K; Smith, SS, 2002
)
1.43
"Allopregnanolone is a neurosteroid which exhibits anxiolytic and anticonvulsant activities through potentiation of the GABA(A) receptor. "( Kinetics of allopregnanolone formation catalyzed by human 3 alpha-hydroxysteroid dehydrogenase type III (AKR1C2).
Jiang, A; LoGrasso, PV; Stearns, BA; Trauger, JW, 2002
)
1.22
"Allopregnanolone is a potent GABAA receptor agonist and produces effects similar to the effects produced by ethanol."( Impairments in spatial learning and memory: ethanol, allopregnanolone, and the hippocampus.
Berry, RB; Matthews, DB; Silvers, JM; Tokunaga, S; White, AM, 2003
)
1.05
"Allopregnanolone (AP) is a potent modulator of the GABAA receptor. "( Increased allopregnanolone levels in the fetal sheep brain following umbilical cord occlusion.
Castillo-Melendez, M; Hirst, JJ; Nguyen, PN; Walker, DW; Yan, EB, 2004
)
1.24
"Allopregnanolone is a progesterone metabolite and GABA-A receptor modulator with benzodiazepine like effects, including decreased learning and memory. "( 3beta-20beta-dihydroxy-5alpha-pregnane (UC1011) antagonism of the GABA potentiation and the learning impairment induced in rats by allopregnanolone.
Backstrom, T; Birzniece, V; Johansson, IM; Lundgren, P; Turkmen, S; Zingmark, E, 2004
)
1.08
"Allopregnanolone is a potent, positive allosteric modulator of GABA(A) receptors."( Pharmacology of catamenial epilepsy.
Reddy, DS, 2004
)
0.8
"Allopregnanolone is a positive allosteric modulator of GABAA receptors, generated by the reduction of 5alpha-dihydroprogesterone (5alpha-DHP) in astrocytes. "( Intracellular oxidation of allopregnanolone by human brain type 10 17beta-hydroxysteroid dehydrogenase.
He, XY; Wegiel, J; Yang, SY, 2005
)
1.17
"Allopregnanolone is a neuroactive steroid with contradictory effects. "( Allopregnanolone concentration and mood--a bimodal association in postmenopausal women treated with oral progesterone.
Andréen, L; Bäckström, T; Bixo, M; Nyberg, S; Sundström-Poromaa, I, 2006
)
1.45
"Allopregnanolone is an effective anticonvulsant against the secondarily generalized component of the seizure, but not against the amygdala focal discharge."( The anticonvulsant effects of progesterone and its metabolites on amygdala-kindled seizures in male rats.
Lonsdale, D; McIntyre Burnham, W; Nylen, K, 2006
)
0.81
"Allopregnanolone is a neurosteroid produced in the brain that can alter the excitability of the CNS. "( Hypoxia potentiates endotoxin-induced allopregnanolone concentrations in the newborn brain.
Billiards, SS; Canny, BJ; Hirst, JJ; Nguyen, PN; Phillips, DJ; Scheerlinck, JP; Walker, DW, 2006
)
1.16
"Allopregnanolone is a metabolite of progesterone and a potent positive modulator of the GABA(A) receptor and produces sedative and anxiolytic effects."( Oral progesterone decreases saccadic eye velocity and increases sedation in women.
Bäckström, T; van Broekhoven, F; Verkes, RJ, 2006
)
0.81
"Allopregnanolone (AP) is a potent GABAergic agonist that suppresses CNS activity, seizure threshold, and excitotoxicity in the adult brain. "( Inhibition of neurosteroid synthesis increases asphyxia-induced brain injury in the late gestation fetal sheep.
Hirst, JJ; Walker, DW; Yan, EB; Yawno, T, 2007
)
0.9
"Allopregnanolone is a known GABA(A) receptor agonist not previously given to men, or to women using oral contraceptives (OC). "( Effects of allopregnanolone on sedation in men, and in women on oral contraceptives.
Bäckström, T; Buitelaar, JK; Smits, P; van Broekhoven, F; van Luijtelaar, G; Verkes, RJ, 2007
)
1.25
"Allopregnanolone is a 5alpha-reduced metabolite of progesterone that potentiates gamma-aminobutyric acid type-A (GABA(A)) receptor activity and produces anxiolytic effects in animal models. "( The anxiolytic-like effects of allopregnanolone vary as a function of intracerebral microinfusion site: the amygdala, medial prefrontal cortex, or hippocampus.
Engin, E; Treit, D, 2007
)
1.17
"Allopregnanolone is a potent neuroactive steroid hormone produced in the brain and in peripheral endocrine glands. "( Aging is associated with changes in allopregnanolone concentrations in brain, endocrine glands and serum in male rats.
Bernardi, F; Casarosa, E; Genazzani, AR; Lanzone, A; Luisi, S; Nappi, RE; Petraglia, F; Purdy, RH; Salvestroni, C, 1998
)
1.13
"Allopregnanolone is a neuroactive steroid involved in modulating behavioral functions, stress, and neuroendocrine axes in rats. "( Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences.
Bernardi, F; Casarosa, E; Genazzani, AR; Luisi, M; Luisi, S; Nappi, RE; Palumbo, M; Petraglia, F; Purdy, RH; Salvestroni, C; Tonetti, A, 1998
)
1.16
"Pregnanolone is a 3alpha-hydroxylated-5beta-reduced metabolite of the female sex steroid hormone progesterone. "( Lack of influence of menstrual cycle and premenstrual syndrome diagnosis on pregnanolone pharmacokinetics.
Andersson, A; Appelblad, P; Bäckström, T; Spigset, O; Sundström, I, 1999
)
1.98
"Allopregnanolone is a neuroactive steroid measurable in peripheral circulation. "( Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients.
Benedetto, C; Bernardi, F; Fadalti, M; Genazzani, AR; Luisi, M; Luisi, S; Nappi, RE; Petraglia, F; Reis, FM, 2000
)
1.27
"Allopregnanolone is a potent anxiolytic, anticonvulsant, sedative and hypnotic GABAergic neurosteroid."( Activation of peripheral mitochondrial benzodiazepine receptors in the hippocampus stimulates allopregnanolone synthesis and produces anxiolytic-like effects in the rat.
Audette, D; Bitran, D; Foley, M; Frye, CA; Leslie, N, 2000
)
1
"Allopregnanolone is a neuroactive steroid synthesized in rat gonads, adrenal cortex, and central nervous system. "( Effects of estradiol and raloxifene analog on brain, adrenal and serum allopregnanolone content in fertile and ovariectomized female rats.
Bernardi, F; Casarosa, E; Farzati, A; Genazzani, AR; Luisi, M; Luisi, S; Monteleone, P; Petraglia, F; Rubino, S; Stomati, M, 2000
)
1.1
"Allopregnanolone (ALLO), is a brain endogenous neurosteroid that binds with high affinity to gamma-aminobutyric acid type A (GABA(A)) receptors and positively modulates the action of GABA at these receptors. "( Brain 5alpha-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation.
Costa, E; Dong, E; Guidotti, A; Matsumoto, K; Nomura, H; Sugaya, I; Takahata, H; Uzunova, V; Watanabe, H, 2001
)
1.13
"Allopregnanolone is a well-established allosteric modulator of the GABAA receptor but its physiological roles within the nervous system remain unclear. "( Physiological roles for the neurosteroid allopregnanolone in the modulation of brain function during pregnancy and parturition.
Herbison, AE, 2001
)
1.13
"Allopregnanolone is a neuroactive steroid present in the brain, but also measurable in systemic circulation. "( Increased response of plasma allopregnanolone to corticotropin-releasing hormone in obese patients.
Bondi, M; Cobellis, L; Del Rio, G; Florio, P; Genazzani, AR; Luisi, S; Menozzi, R; Petraglia, F, 2002
)
1.15
"Allopregnanolone is a neuroactive steroid that, like ethanol (EtOH), has stimulant, anxiolytic, ataxic, and depressant effects. "( Sensitivity to the locomotor stimulant effects of ethanol and allopregnanolone is influenced by common genes.
McKinnon, CS; Miller, MN; Palmer, AA; Phillips, TJ, 2002
)
1.11

Effects

Allopregnanolone has a trophic role in regulating development, maintaining normal levels of apoptosis and increasing myelination during late gestation in the brain.

Allopregnanolone (3α-THP) has been one of the most studied progesterone metabolites for decades. It has a trophic role in regulating development, maintaining normal levels of apoptosis and increasing myelination during late gestation in the brain. Allopreganolone has been shown to enhance GABA neurotransmission.

ExcerptReferenceRelevance
"Allopregnanolone (ALLO) has a crucial role in brain development and remodeling. "( Brain intracrinology of allopregnanolone during pregnancy and hormonal contraception.
Ansaldi, Y; Genazzani, AR; Pluchino, N, 2019
)
1.37
"Allopregnanolone has a trophic role in regulating development, maintaining normal levels of apoptosis and increasing myelination during late gestation in the brain."( Neuroactive steroids in pregnancy: key regulatory and protective roles in the foetal brain.
Hirst, JJ; Kelleher, MA; Palliser, HK; Walker, DW, 2014
)
0.88
"Allopregnanolone (3α-THP) has been one of the most studied progesterone metabolites for decades. "( Allopregnanolone: Metabolism, Mechanisms of Action, and Its Role in Cancer.
Camacho-Arroyo, I; Zamora-Sánchez, CJ, 2022
)
1.84
"Allopregnanolone (ALLO) has a crucial role in brain development and remodeling. "( Brain intracrinology of allopregnanolone during pregnancy and hormonal contraception.
Ansaldi, Y; Genazzani, AR; Pluchino, N, 2019
)
1.37
"Allopregnanolone has a trophic role in regulating development, maintaining normal levels of apoptosis and increasing myelination during late gestation in the brain."( Neuroactive steroids in pregnancy: key regulatory and protective roles in the foetal brain.
Hirst, JJ; Kelleher, MA; Palliser, HK; Walker, DW, 2014
)
0.88
"Allopregnanolone has shown potent anticonvulsant activity in the adult brain. "( On the anticonvulsant effect of allopregnanolone (a neurosteroid) in neonatal rats.
Chopra, K; Dhir, A, 2015
)
1.25
"Allopregnanolone (ALLO) has important modulatory effects in the hippocampus during the postnatal period where the adult pattern of inhibitory transmission is being established."( Neonatal neurosteroid levels are determinant in shaping adult prepulse inhibition response to hippocampal allopregnanolone in rats.
Darbra, S; Modol, L; Pallarès, M; Vallée, M, 2013
)
1.08
"Allopregnanolone has been shown to enhance GABA neurotransmission, whereas its isomer epiallopregnanolone does not have this property."( Allopregnanolone, a progesterone metabolite, enhances behavioral recovery and decreases neuronal loss after traumatic brain injury.
He, J; Hoffman, SW; Stein, DG, 2004
)
1.36
"Allopregnanolone has anticonvulsant effects--and a good therapeutic index--against the secondarily generalized component of amygdala-kindled seizures."( The anticonvulsant effects of allopregnanolone against amygdala-kindled seizures in female rats.
Burnham, WM; Lonsdale, D, 2007
)
1.1

Actions

Allopregnanolone levels increase during pregnancy and decrease substantially after birth. The drug also plays a key role in the foetal brain, where it promotes development and is neuroprotective.

ExcerptReferenceRelevance
"Allopregnanolone levels increase during pregnancy and decrease substantially after birth."( Brexanolone: A Novel Drug for the Treatment of Postpartum Depression.
Nguyen, DR; Patatanian, E, 2022
)
1.2
"Allopregnanolone plays an important role in the ovarian pathophysiology."( Allopregnanolone alters follicular and luteal dynamics during the estrous cycle.
Asensio, JA; Cáceres, ARR; Laconi, MR; Parborell, F; Pelegrina, LT; Sanhueza, MLÁ; Scotti, L, 2018
)
1.52
"Allopregnanolone also plays a key role in the foetal brain, where it promotes development and is neuroprotective."( Allopregnanolone in the brain: protecting pregnancy and birth outcomes.
Brunton, PJ; Hirst, JJ; Russell, JA, 2014
)
1.44
"Allopregnanolone plays a role in the stress response and homeostasis. "( Changes in stress-stimulated allopregnanolone levels induced by neonatal estradiol treatment are associated with enhanced dopamine release in adult female rats: reversal by progesterone administration.
Catzeddu, S; Concas, A; Dazzi, L; Lallai, V; Locci, A; Pisu, MG; Porcu, P; Serra, M; Serra, V, 2017
)
1.29
"Allopregnanolone induced an increase in LHRH release."( Allopregnanolone induces LHRH and glutamate release through NMDA receptor modulation.
Cabrera, R; Giuliani, FA; Laconi, M; Mohn, CE; Rettori, V; Yunes, R, 2011
)
1.41
"Allopregnanolone was found to produce significant anxiolytic-like effects at a dose of 8 mg/kg."( The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with GABA(A) receptors.
Akwa, Y; Britton, KT; Brot, MD; Koob, GF; Purdy, RH, 1997
)
1.03

Treatment

Allopregnanolone treatment was seen to induce a partial tolerance against acute allopreg nanolone effects in the Morris water maze. Allopreg Nanolone also impacted significantly GABA metabolism, oxidative stress, and some of the mitochondria-related outcomes.

ExcerptReferenceRelevance
"Allopregnanolone treatment impacted significantly GABA metabolism, oxidative stress, and some of the mitochondria-related outcomes."( Allopregnanolone Treatment Improves Plasma Metabolomic Profile Associated with GABA Metabolism in Fragile X-Associated Tremor/Ataxia Syndrome: a Pilot Study.
Carrillo, NR; Giulivi, C; Hagerman, RJ; Napoli, E; Rogawski, M; Schneider, A; Tassone, F; Trivedi, A; Wang, JY, 2019
)
1.55
"Allopregnanolone treatment was also neuroprotective."( Neuroprotection by steroids after neurotrauma in organotypic spinal cord cultures: a key role for progesterone receptors and steroidal modulators of GABA(A) receptors.
De Nicola, AF; Ghoumari, AM; Guennoun, R; Labombarda, F; Liere, P; Schumacher, M, 2013
)
0.87
"Allopregnanolone treatment was not effective in raising fetal plasma concentrations after prenatal stress suggesting a stress-induced dysregulation of neurosteroid pathways during gestation."( Effects of prenatal stress on fetal neurodevelopment and responses to maternal neurosteroid treatment in Guinea pigs.
Bennett, GA; Hirst, JJ; Palliser, HK; Saxby, B; Walker, DW, 2013
)
0.87
"Allopregnanolone and VEH treatment was then discountinued and the sucrose-maintained rats were administered priming injections of saline, yohimbine, or yohimbine + ALLO."( Differential effects of allopregnanolone on the escalation of cocaine self-administration and sucrose intake in female rats.
Anker, JJ; Carroll, ME; Zlebnik, NE, 2010
)
1.14
"Allopregnanolone treatment of the experimental autoimmune encephalomyelitis mouse model limited the associated neuropathology, including neuroinflammation, myelin and axonal injury and reduced neurobehavioral deficits (P < 0.05)."( Impaired neurosteroid synthesis in multiple sclerosis.
Baker, GB; Ellestad, KK; Han, MH; Maingat, F; Noorbakhsh, F; Power, C; Steinman, L; Warren, KG, 2011
)
0.85
"Allopregnanolone-treated rats showed better performance in the MWM compared to the vehicle-treated injury group. "( Allopregnanolone, a progesterone metabolite, enhances behavioral recovery and decreases neuronal loss after traumatic brain injury.
He, J; Hoffman, SW; Stein, DG, 2004
)
1.44
"Allopregnanolone treatment was therefore seen to induce a partial tolerance against acute allopregnanolone effects in the Morris water maze."( Tolerance development to Morris water maze test impairments induced by acute allopregnanolone.
Bäckström, T; Birzniece, V; Johansson, IM; Löfgren, M; Türkmen, S, 2006
)
1.04
"Pregnanolone treatment decreased the amplitude of the N25 peak of the SEP (89.9+/-2.8% of control, P < 0.05) evoked following stimulation of the skin of the upper lip."( Effect of pregnane steroids on electrocortical activity and somatosensory evoked potentials in fetal sheep.
Hirst, JJ; Nicol, MB; Walker, DW, 1998
)
1.02
"Posttreatment allopregnanolone levels were significantly lower in the improved compared with the unimproved subjects."( Allopregnanolone levels and symptom improvement in severe premenstrual syndrome.
Freeman, EW; Frye, CA; Martin, PA; Rickels, K; Smith, SS, 2002
)
1.2

Toxicity

ExcerptReferenceRelevance
"Because the treatment and management of neuropathic pain are extremely complicated, the characterization of novel analgesics and neuroprotectors with safe toxicological profiles is a crucial need to develop efficient therapies."( Potential role of allopregnanolone for a safe and effective therapy of neuropathic pain.
Mensah-Nyagan, AG; Meyer, L; Patte-Mensah, C; Taleb, O, 2014
)
0.72
" Treatment-emergent adverse events occurred in 43 (86%) of 50 patients in the ganaxolone group and in 45 (88%) of 51 patients in the placebo group."( Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.
Aimetti, AA; Amin, S; Bahi-Buisson, N; Benke, TA; Cross, JH; Demarest, ST; Devinsky, O; Fleming, TR; Gasior, M; Knight, EMP; Olson, HE; Specchio, N, 2022
)
0.72
" These results further suggest that AP in the PFC mediates the adverse effects of stress on the severity of tics and other TS-related manifestations."( Prefrontal allopregnanolone mediates the adverse effects of acute stress in a mouse model of tic pathophysiology.
Anderson, CJ; Bortolato, M; Cadeddu, R; Flanagan, D; Nordkild, P; Odeh, K; Pinna, G; Pittenger, C; Santovito, LS; Van Zandt, M, 2023
)
1.26

Pharmacokinetics

Pregnanolone emulsion was administered intravenously as bolus doses to six young healthy male volunteers in a preliminary pharmacokinetic and pharmacodynamic study.

ExcerptReferenceRelevance
" Drug uptake and retention in extravisceral tissues, represented here by the hindquarters, can result in the mean total body drug clearance being overestimated when determined by traditional systemic pharmacokinetic methods."( Uptake and elution of chlormethiazole, meperidine, and minaxolone in the hindquarters of sheep: implications for clearance calculations.
Carapetis, RJ; Mather, LE; McLean, CF; Runciman, WB; Upton, RN, 1991
)
0.28
"Pregnanolone emulsion, a new steroid anaesthetic agent, was administered intravenously as bolus doses to six young healthy male volunteers in a preliminary pharmacokinetic and pharmacodynamic study."( Pregnanolone emulsion. A preliminary pharmacokinetic and pharmacodynamic study of a new intravenous anaesthetic agent.
Bäckstrøm, T; Carl, P; Høgskilde, S; Karlen, B; Lindholm, M; Nielsen, JW; Sørensen, MB, 1990
)
3.16
" Further experimental evidence in support of this finding was the lack of dose dependence in any pharmacokinetic parameter following bolus doses through the clinical range of 12."( Minaxolone, a new steroidal anesthetic. Pharmacokinetics and organ extraction in sheep.
Gourlay, GK; Mather, LE; Parkin, KS,
)
0.13
" The decay in the plasma drug concentrations after the infusion could be fitted to a bi-exponential equation, indicating that the steroids were distributed according to an open two-compartment pharmacokinetic model."( Alphadione and minaxolone pharmacokinetics.
Prys-Roberts, C; Sear, JW, 1981
)
0.26
" Venous blood was collected to establish a concentration-effect relation using the median frequency as a pharmacodynamic parameter for hypnotic effect, and with analysis of data with the sigmoidal Emax model."( EEG analysis and pharmacodynamic modelling after intravenous bolus injection of eltanolone (pregnanolone).
Biburger, G; Brune, K; Dinkel, M; Geisslinger, G; Hering, W; Rügheimer, E; Schlecht, R, 1995
)
0.51
"kg-1 over 45 s to eight healthy male volunteers to evaluate some of its pharmacokinetic and pharmacodynamic effects."( Pharmacokinetics and pharmacodynamics of eltanolone (pregnanolone), a new steroid intravenous anaesthetic, in humans.
Bach, V; Carl, P; Grälls, M; Høgskilde, S; Jacobsen, J; Lang-Jensen, T; Sørensen, MB; Widlund, L, 1994
)
0.54
" Until now, however, no investigations have addressed the infusion pharmacokinetics of eltanolone or used electroencephalographic effect data for full pharmacodynamic modeling."( Pharmacokinetic-pharmacodynamic modeling of the new steroid hypnotic eltanolone in healthy volunteers.
Dinkel, M; Geisslinger, G; Hering, WJ; Ihmsen, H; Langer, H; Schüttler, J; Uhrlau, C, 1996
)
0.29
" During and after the infusion, electroencephalographic data were recorded as a continuous pharmacodynamic parameter to measure the hypnotic effect."( Pharmacokinetic-pharmacodynamic modeling of the new steroid hypnotic eltanolone in healthy volunteers.
Dinkel, M; Geisslinger, G; Hering, WJ; Ihmsen, H; Langer, H; Schüttler, J; Uhrlau, C, 1996
)
0.29
"The pharmacokinetic model parameters of eltanolone were characterized by a high total clearance (1."( Pharmacokinetic-pharmacodynamic modeling of the new steroid hypnotic eltanolone in healthy volunteers.
Dinkel, M; Geisslinger, G; Hering, WJ; Ihmsen, H; Langer, H; Schüttler, J; Uhrlau, C, 1996
)
0.29
"Mean pregnanolone elimination half-life varied between 28."( Lack of influence of menstrual cycle and premenstrual syndrome diagnosis on pregnanolone pharmacokinetics.
Andersson, A; Appelblad, P; Bäckström, T; Spigset, O; Sundström, I, 1999
)
1.05
" Due to its simplicity and sensitivity this method can be used on a routine basis for pharmacokinetic analysis of neuroactive steroids."( High-performance liquid chromatography of the neuroactive steroids alphaxalone and pregnanolone in plasma using dansyl hydrazine as fluorescent label: application to a pharmacokinetic-pharmacodynamic study in rats.
Danhof, M; Gladdines, WW; Irth, H; Smulders, CJ; van der Graaf, PH; Visser, SA, 2000
)
0.53
" The method was used for the routine analysis of ganaxolone in rat, monkey, dog and human plasma and summary of the pharmacokinetic data are presented."( A high-performance liquid chromatography-tandem mass spectrometric method for the determination of pharmacokinetics of ganaxolone in rat, monkey, dog and human plasma.
Chien, B; Lam, GN; Ram, K, 2001
)
0.31
"We have evaluated and compared the pharmacokinetic and pharmacodynamic properties of allopregnanolone and pregnanolone at induction of anaesthesia in male rats."( Evaluation and comparison of the pharmacokinetic and pharmacodynamic properties of allopregnanolone and pregnanolone at induction of anaesthesia in the male rat.
Bäckström, T; Wahlström, G; Wang, MD; Zhu, D, 2001
)
0.76
" Blood samples for the analysis of progesterone, allopregnanolone and pregnanolone were collected, and pharmacokinetic parameters were calculated."( Pharmacokinetics of progesterone and its metabolites allopregnanolone and pregnanolone after oral administration of low-dose progesterone.
Andersson, A; Andréen, L; Bäckström, T; Nyberg, S; Spigset, O, 2006
)
0.83
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"This manuscript addresses key pharmacokinetic issues in support of the development of a potent candidate lipid-lowering drug molecule, 16-dehydropregnenolone (DHP)."( Preclinical pharmacokinetics, dose proportionality, gender difference and protein binding study of 16-dehydropregnenolone, an antihyperlipidemic agent, in rats.
Gupta, RC; Singh, SK; Suryawanshi, S, 2011
)
0.37
" Pharmacokinetic studies of DHP after intravenous and oral administration were carried out to assess any gender effect."( Preclinical pharmacokinetics, dose proportionality, gender difference and protein binding study of 16-dehydropregnenolone, an antihyperlipidemic agent, in rats.
Gupta, RC; Singh, SK; Suryawanshi, S, 2011
)
0.37
" An increase in the oral dose led to a disproportionate change in peak concentration (C(max) ) and AUC, indicating variable absorption."( Preclinical pharmacokinetics, dose proportionality, gender difference and protein binding study of 16-dehydropregnenolone, an antihyperlipidemic agent, in rats.
Gupta, RC; Singh, SK; Suryawanshi, S, 2011
)
0.37
" Pharmacokinetic analyses of intravenous allopregnanolone in rabbit and mouse indicated that peak plasma and brain levels (3-fold brain/plasma ratios) at 5min were sufficient to activate neuroregenerative responses at sub-sedative doses."( Allopregnanolone preclinical acute pharmacokinetic and pharmacodynamic studies to predict tolerability and efficacy for Alzheimer's disease.
Bauer, G; Brinton, RD; Irwin, RW; Loya, CM; Rodgers, KE; Rogawski, MA; Salituro, FG; Solinsky, CM, 2015
)
1.23

Bioavailability

ExcerptReferenceRelevance
" In animal studies, compound 6 (CCD 1042) is an orally active anticonvulsant, while the naturally occurring progesterone metabolites 1 and 2 are inactive when administered orally, suggesting that 3 beta-substitution slows metabolism of the 3-hydroxyl, resulting in orally bioavailable steroid modulators of the GABAA receptor."( Synthesis and in vitro activity of 3 beta-substituted-3 alpha-hydroxypregnan-20-ones: allosteric modulators of the GABAA receptor.
Acosta-Burruel, M; Alauddin, M; Bolger, MB; Gee, KW; Hawkinson, JE; Hogenkamp, DJ; Kimbrough, CL; Lan, NC; Tahir, SH; Upasani, RB; Whittemore, ER; Woodward, RM, 1997
)
0.3
" In an attempt to develop therapeutic agents which would maintain the pharmacological profiles of endogeneous neuroactive steroids but with increased oral bioavailability and reduced metabolic liability, we explored simple substitutions at the 3 beta-position of the endogenous neuroactive steroid, 3 alpha-hydroxy-5 alpha-pregnan-20-one (3 alpha, 5 alpha-P)."( Anxiolytic and anticonvulsant activity of a synthetic neuroactive steroid Co 3-0593.
Belluzzi, J; Gee, KW; Hawkinson, JE; Hogenkamp, D; Lan, NC; Stein, L; Upasani, R; Wieland, S; Wood, PL, 1997
)
0.3
" Neurosteroid replacement is a potential approach to therapy, but natural neurosteroids have poor bioavailability and may be converted to metabolites with undesired progestational activity."( Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy.
Reddy, DS; Rogawski, MA, 2000
)
0.31
" Synthetic neurosteroids that exhibit better bioavailability and efficacy and drugs that enhance neurosteroid synthesis have therapeutic potential in anxiety, epilepsy, and other brain disorders."( Neurosteroids: endogenous role in the human brain and therapeutic potentials.
Reddy, DS, 2010
)
0.36
" DHP showed low systemic oral bioavailability and exhibited dose-independent pharmacokinetics and gender differences."( Preclinical pharmacokinetics, dose proportionality, gender difference and protein binding study of 16-dehydropregnenolone, an antihyperlipidemic agent, in rats.
Gupta, RC; Singh, SK; Suryawanshi, S, 2011
)
0.37
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" However, allopregnanolone presents low bioavailability and extensive hepatic metabolism, limiting its use as a drug."( Allopregnanolone: An overview on its synthesis and effects.
Cioffi, L; Diviccaro, S; Falvo, E; Giatti, S; Melcangi, RC, 2022
)
1.64
" The steroid structure was chemically altered to improve bioavailability and create an oral dosage form."( Neuroactive steroids - new possibilities in the treatment of postpartum depression.
Adamičková, A; Gažová, A; Hrubá, O; Massarová, P; Vranecová, K; Žigová, L, 2022
)
0.72

Dosage Studied

Caffeine also increased the plasma concentrations of pregnenolone and progesterone with a dose-response relation similar to that observed in the brain. This is a novel site of action for fluoxetine, with implications for the development of new agents and/or dosing regimens to raise brain allopregnanolone.

ExcerptRelevanceReference
" The dose-response curves of the steroids differed, however, in that cyproterone acetate produced a greater mean stimulation of the enzyme at concentrations less than approximately 25 muM, whereas, at higher concentrations, cyproterone was the more effective inducer."( Cyproterone-mediated stimulation of delta-aminolevulinic acid synthetase in chick embryo liver cells.
Gidari, AS; Lane, SE; Levere, RD, 1976
)
0.26
" The anaesthetic was administered as repeated intravenous bolus injections, doubling the dosage with each injection."( Cardiovascular effects of pregnanolone emulsion: an experimental study in artificially ventilated dogs.
Bredgaard Sørensen, M; Høgskilde, S; Olesen, HP; Sjøntoft, E; Strøm, J; Wagner, J, 1991
)
0.58
" The dose-response relationships for potentiation of 1 microM GABA-mediated chloride currents were studied for [3S-(3 alpha, 3a alpha, 5a beta, 7 beta, 9a alpha, 9b beta)]-1- [dodecahydro-7-(2-hydroxyethyl)-3a-methyl-1H-benz[e]inden-3- yl]ethanone (3), steroid 7, 3 alpha-hydroxy-5 alpha-pregnan-20-one (5), and the analogous 7 alpha-(2-hydroxyethyl)benz[e]indene analogue of steroid 5 (compound 1)."( Neurosteroid analogues. 3. The synthesis and electrophysiological evaluation of benz[e]indene congeners of neuroactive steroids having the 5 beta-configuration.
Covey, DF; Han, M; Hu, Y; Zorumski, CF, 1995
)
0.29
" To determine whether the cardiac effects of eltanolone are mediated by indirect sympathetic activation, the same dose-response curve was studied in another group of five hearts depleted of catecholamine with reserpine treatment."( Effects of eltanolone on myocardial performance and coronary flow in intact and catecholamine-depleted isolated rabbit hearts.
Abdenour, L; Coriat, P; Mouren, S; Souktani, R, 1996
)
0.29
" A cumulative dosing procedure was used to assess changes in the potency of ethanol and an endogenous anxiolytic steroid in the follicular versus the luteal phase of the menstrual cycle."( Discriminative stimulus effects of ethanol and 3 alpha-hydroxy-5 alpha-pregnan-20-one in relation to menstrual cycle phase in cynomolgus monkeys (Macaca fascicularis).
Azarov, A; Grant, KA; Purdy, RH; Shively, CA, 1997
)
0.3
" The effects of the steroid solvents albumin and beta-cyclodextrin were assessed by dose-response curves."( Pregnenolone sulphate and pregnenolone do not interact with 5 beta-pregnanolone- and hexobarbitone-induced anaesthesia in the rat.
Bäckström, T; Wahlström, G; Wang, MD, 1997
)
0.53
"The anesthetic induction agents were repeated at the same dosage when cardiopulmonary bypass was instituted."( Bolus administration of eltanolone, thiopental, or etomidate does not affect systemic vascular resistance during cardiopulmonary bypass.
Jänicke, U; Martin, K; Ott, E; Tassani, P, 1997
)
0.3
" Chronic dosing with minaxolone (100 mg/kg, orally, once daily for 7 days) resulted in a loss of sedative response to an acute dose of the drug, indicating development of tolerance."( Development of tolerance in mice to the sedative effects of the neuroactive steroid minaxolone following chronic exposure.
Ford, E; Hagan, RM; Marshall, FH; Mullings, J; Oakley, NR; Stratton, SC; Worton, SP, 1997
)
0.3
" The pharmacokinetics of eltanolone appear to be linear over the dosage range studied."( Pharmacokinetics of eltanolone following bolus injection and constant rate infusion.
Nilsson, A; Parivar, K; Wessén, A; Widman, M, 1996
)
0.29
"Ninety-six healthy male and female volunteers received ganaxolone in a variety of formulations, doses, and dosing regimens."( Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity.
Ashbrook, DW; Lee, DA; Monaghan, EP; Navalta, LA; Shum, L, 1997
)
0.3
" On the day after the chronic treatment protocol, the dose-response relationship for protection in the pentylenetetrazol seizure test was obtained."( Lack of anticonvulsant tolerance to the neuroactive steroid pregnanolone in mice.
Carroll, DM; Grossman, AB; Kokate, TG; Pannell, LK; Rajamani, U; Rogawski, MA; Yamaguchi, S, 1998
)
0.54
" When co-administered in low dosage with halothane, the drug prevented initiation of the MH syndrome in four of eight pigs and attenuated its progress in the remainder."( Eltanolone (5-beta-pregnanolone) does not trigger, and attenuates halothane triggering of, malignant hyperthermia in malignant hyperthermia susceptible swine.
Dyer, RA; Harrison, GG; James, MF; Llewellyn, RL, 1999
)
0.63
"0 mg/kg dosage of 3 alpha,5 alpha-THP."( Prenatal stress reduces the effectiveness of the neurosteroid 3 alpha,5 alpha-THP to block kainic-acid-induced seizures.
Bayon, LE; Frye, CA, 1999
)
0.3
" A cumulative dosing procedure was used to test discriminative stimulus effects of ethanol (0."( The influence of menstrual cycle phase on sensitivity to ethanol-like discriminative stimulus effects of GABA(A)-positive modulators.
Azarov, AV; Grant, KA; Green, KL; Purdy, RH; Szeliga, KT, 1999
)
0.3
"1-1 microM) of muscimol, and the muscimol dose-response (0."( Brain allopregnanolone regulates the potency of the GABA(A) receptor agonist muscimol.
Costa, E; Guidotti, A; Matsumoto, K; Mienville, JM; Pinna, G; Puia, G; Uzunova, V, 2000
)
0.71
" Pentobarbital had no statistically significant effect on the cocaine dose-response function."( Neuroactive steroids attenuate cocaine-induced sucrose intake in rats, but not cocaine-induced hyperactivity in mice.
Carter, RB; Huber, M; Suruki, M; Vanover, KE; Wilent, WB, 2000
)
0.31
" Caffeine also increased the plasma concentrations of pregnenolone and progesterone with a dose-response relation similar to that observed in the brain, whereas the caffeine-induced increase in the plasma concentration of allopregnanolone was maximal at a dose of 50 mg/kg."( Caffeine-induced increases in the brain and plasma concentrations of neuroactive steroids in the rat.
Biggio, G; Concas, A; Porcu, P; Purdy, RH; Serra, M; Sogliano, C, 2000
)
0.49
" Additionally, ethanol caused less than a 2-fold shift to the left in the dose-response function of Co 2-6749 in the rotorod procedure in rats."( Characterization of the anxiolytic properties of a novel neuroactive steroid, Co 2-6749 (GMA-839; WAY-141839; 3alpha, 21-dihydroxy-3beta-trifluoromethyl-19-nor-5beta-pregnan-20-one), a selective modulator of gamma-aminobutyric acid(A) receptors.
Barrett, JE; Belluzzi, JD; Carter, RB; Hawkinson, JE; Lan, NC; Rosenzweig-Lipson, S; Stein, L; Vanover, KE; Wood, PL, 2000
)
0.31
" Dosing occurred three times per day: immediately after breakfast, lunch, and dinner."( Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group.
Abou-Khalil, BW; Blum, D; Data, JL; Laxer, K; Lee, DA; Monaghan, EP; Morrell, MJ, 2000
)
0.31
" However, infusions of either 3alpha-5alpha-P or pentobarbital in the hippocampus failed to substitute for ethanol and produced inverted U-shaped dose-response curves."( Allopregnanolone and pentobarbital infused into the nucleus accumbens substitute for the discriminative stimulus effects of ethanol.
Hodge, CW; Kelley, SP; Mehmert, KK; Nannini, MA; Olive, MF, 2001
)
0.87
"Rhesus monkeys responding under a multiple fixed ratio (FR:FR) schedule of food presentation and stimulus-shock termination received GABA(A) modulators under cumulative dosing procedures."( The negative GABA(A) modulator methyl beta-carboline-3-carboxylate attenuates the behavioral effects of the positive GABA(A) modulators triazolam and pregnanolone in rhesus monkeys.
France, CP; McMahon, LR, 2001
)
0.51
" The modulatory effects of PS, but not 3alpha5betaS, on dose-response curves for NMDA, glutamate, and glycine are consistent with a two-state model in which PS either stabilizes or destabilizes the active state of the receptor, depending upon which NR2 subunit is present."( Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids.
Farb, DH; Gibbs, TT; Malayev, A, 2002
)
0.31
" When neocortical slices were treated in vitro for 3 h with 10 microM SKF, ALLO was also reduced (25-30%) and in addition, the GABA dose-response curve was shifted to the right; however this shift was not as marked as the shift in the slices obtained from mice treated with SKF, in keeping with the smaller decrease of the ALLO content in these slices."( On the putative physiological role of allopregnanolone on GABA(A) receptor function.
Costa, E; Guidotti, A; Matsumoto, K; Mienville, JM; Puia, G; Takahata, H; Watanabe, H, 2003
)
0.58
" Dose-response (D-R) curves and kinetic measurements of GABA rho(1) currents were carried out in the presence or absence of antagonists."( Studies on the mechanisms of action of picrotoxin, quercetin and pregnanolone at the GABA rho 1 receptor.
Calvo, DJ; Goutman, JD, 2004
)
0.56
" A dose-response curve revealed a bell-shaped effect of 3alpha,5alpha-THP on ePSA-NCAM+ progenitor proliferation, with greatest stimulation at nanomolar concentrations."( 3alpha,5alpha-Tetrahydroprogesterone (allopregnanolone) and gamma-aminobutyric acid: autocrine/paracrine interactions in the control of neonatal PSA-NCAM+ progenitor proliferation.
Avellana-Adalid, V; Baron-Van Evercooren, A; Cadepond, F; El-Etr, M; Gago, N; Samuel, D; Sananès, N; Schumacher, M, 2004
)
0.59
" Dose-response curves for fluoxetine (0."( Synergistic interaction between ketoconazole and several antidepressant drugs with allopregnanolone treatments in ovariectomized Wistar rats forced to swim.
García, JP; Jaramillo, MT; Lopez, JI; Molina-Hernández, M; Tellez-Alcántara, NP, 2004
)
0.55
" Multiple doses of progesterone, 5alpha-dihydroprogesterone, or allopregnanolone were administered in separate dose-response studies."( The anticonvulsant effects of progesterone and its metabolites on amygdala-kindled seizures in male rats.
Lonsdale, D; McIntyre Burnham, W; Nylen, K, 2006
)
0.57
" One of the three kinetic effects evident in channel potentiation by 3alpha5alphaP, prolongation of the longest-lived open time component (OT3), was affected by ethanol with the midpoint of its dose-response curve moved to lower steroid concentrations by 2 orders of magnitude without significantly affecting the maximal effect."( Ethanol modulates the interaction of the endogenous neurosteroid allopregnanolone with the alpha1beta2gamma2L GABAA receptor.
Akk, G; Evers, AS; Li, P; Manion, BD; Steinbach, JH, 2007
)
0.57
" Withdrawal of female rats from prolonged systemic dosing with progesterone leads to increased numbers of alpha4, beta1 and delta GABA(A) receptor subunit-immunoreactive neurones in the PAG."( GABA in the female brain -- oestrous cycle-related changes in GABAergic function in the periaqueductal grey matter.
Lovick, TA, 2008
)
0.35
" In the periaqueductal grey (PAG) matter, upregulation of alpha4beta1delta GABA(A) receptors occurs as progesterone levels fall during late dioestrus (LD) or during withdrawal from an exogenous progesterone dosing regime."( Progesterone withdrawal-evoked plasticity of neural function in the female periaqueductal grey matter.
Devall, AJ; Lovick, TA, 2009
)
0.35
" However, the whole-cell GABA dose-response and the single-channel effective opening rate curves were shifted to higher GABA concentrations, suggesting that the concatemeric receptors have a lower affinity to GABA."( Activation and modulation of concatemeric GABA-A receptors expressed in human embryonic kidney cells.
Akk, G; Bracamontes, J; Li, P; Steinbach, JH, 2009
)
0.35
" In contrast, multiple doses of DHEA consistently decreased intake of an 18% ethanol concentration in both groups after repeated injections and 3 doses of DHEA (10, 32, and 56 mg/kg) administered with various ethanol concentrations dose-dependently shifted the ethanol-concentration curves for the volume and dosage of ethanol consumed downward."( Effects of pregnanolone and dehydroepiandrosterone on ethanol intake in rats administered ethanol or saline during adolescence.
Gurkovskaya, OV; Leonard, ST; Lewis, PB; Winsauer, PJ, 2009
)
0.74
" A dose-response study on midazolam in the elevated plus maze test was carried out in adulthood (experiment 1) in order to screen GABAA-benzodiazepine function alterations."( Effects of early postnatal allopregnanolone administration on elevated plus maze anxiety scores in adult male Wistar rats.
Darbra, S; Pallarès, M, 2012
)
0.66
" Critical to success was a dosing and treatment regimen that was consistent with the temporal requirements of systems biology of regeneration in brain."( Allopregnanolone as regenerative therapeutic for Alzheimer's disease: translational development and clinical promise.
Brinton, RD; Irwin, RW, 2014
)
0.96
" E4 at a dosage of 5mg/kg/day increased AP levels in different brain areas and in the serum of OVX animals."( Effect of estetrol administration on brain and serum allopregnanolone in intact and ovariectomized rats.
Casarosa, E; Genazzani, A; Genazzani, AR; Giannini, A; Petignat, P; Pluchino, N; Russo, M; Russo, N; Santoro, AN, 2014
)
0.65
" Co-application of neurosteroids with etomidate can significantly reduce dosage requirements for the anaesthetic, and is a potentially beneficial combination to reduce undesired side effects."( The neurosteroid 5β-pregnan-3α-ol-20-one enhances actions of etomidate as a positive allosteric modulator of α1β2γ2L GABAA receptors.
Akk, G; Bracamontes, JR; Evers, AS; Li, P; Manion, BD; Mennerick, S; Steinbach, JH, 2014
)
0.4
" This is a novel site of action for fluoxetine, with implications for the development of new agents and/or dosing regimens to raise brain allopregnanolone."( Fluoxetine elevates allopregnanolone in female rat brain but inhibits a steroid microsomal dehydrogenase rather than activating an aldo-keto reductase.
Cockcroft, S; Devall, AJ; Fry, JP; Honour, JW; Li, KY; Lovick, TA, 2014
)
0.91
" However, Gelsemium is a known toxic plant, and its toxicity limits its appropriate dosage and clinical use."( Gelsemium analgesia and the spinal glycine receptor/allopregnanolone pathway.
Wang, YX; Zhang, JY, 2015
)
0.66
"Withdrawal from long-term dosing with exogenous progesterone precipitates increased anxiety-linked changes in behavior in animal models due to the abrupt decrease in brain concentration of allopregnanolone (ALLO), a neuroactive metabolite of progesterone."( Elevation of brain allopregnanolone rather than 5-HT release by short term, low dose fluoxetine treatment prevents the estrous cycle-linked increase in stress sensitivity in female rats.
Brandão, ML; Devall, AJ; Fry, JP; Honour, JW; Lovick, TA; Santos, JM, 2015
)
0.92
" From the dose-response functions, ED50s (i."( Differential interactions engendered by benzodiazepine and neuroactive steroid combinations on schedule-controlled responding in rats.
Gunter, BW; Platt, DM; Rowlett, JK, 2015
)
0.42
" This suggests that clinical trials designed to test neuroactive steroid therapeutics in PTSD may benefit from such considerations; typical continuous dosing regimens may not be optimal."( Neuroactive steroids and PTSD treatment.
Liang, JJ; Locci, A; Marx, CE; Nillni, YI; Pineles, SL; Pinna, G; Rasmusson, AM; Scioli-Salter, ER, 2017
)
0.46
"26 healthy women completed the pharmacokinetic phase I study and the dosing in the following trial was adjusted according to the results."( Treatment of premenstrual dysphoric disorder with the GABA
Andréen, L; Bäckström, T; Bixo, M; Ehrenborg, A; Ekberg, K; Hirschberg, AL; Jonasson, AF; Poromaa, IS; Timby, E; Wulff, M, 2017
)
0.46
" Future investigations of ganaxolone may benefit from higher dosing, rigorous monitoring of dosing adherence, a longer length of placebo-controlled testing, and targeting of treatment to PTSD subpopulations with demonstrably dysregulated pre-treatment neuroactive steroid levels."( A randomized controlled trial of ganaxolone in posttraumatic stress disorder.
Cusin, C; Farfel, GM; Geracioti, TD; Hamner, MB; Jain, S; Lang, AJ; Lohr, J; Marx, CE; Naylor, JC; Raman, R; Rasmusson, AM; Rosse, R; Stein, MB; Summerall, L; Sun, X; Tsai, J, 2017
)
0.46
" As the optimal XBD173 dosing exerting the maximal beneficial action in EAE mice is the lower 10mg/kg dose, the paper opens interesting perspectives for the development of efficient and safe therapies against MS with slight or no side-effects."( The translocator protein ligand XBD173 improves clinical symptoms and neuropathological markers in the SJL/J mouse model of multiple sclerosis.
Benyounes, J; Bihel, F; Collongues, N; De Seze, J; Hallé, F; Klein, C; Leva, G; Mensah-Nyagan, AG; Patte-Mensah, C, 2017
)
0.46
" Different dose-response curves were demonstrated for AP and the ANS."( Evidence for effective structure-based neuromodulatory effects of new analogues of neurosteroid allopregnanolone.
Geoffroy, P; Kemmel, V; Mensah-Nyagan, AG; Meyer, L; Miesch, M; Patte-Mensah, C; Taleb, O, 2018
)
0.7
" However, dosing studies are required to reduce the burden of unwanted side effects."( Neurosteroid replacement therapy using the allopregnanolone-analogue ganaxolone following preterm birth in male guinea pigs.
Berry, MJ; Dyson, RM; Gray, C; Hirst, JJ; Palliser, HK; Shaw, JC, 2019
)
0.77
" A discussion of these obstacles as well as pharmacokinetics, monitoring, and dosing is provided."( Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations.
Leader, LD; O'Connell, M; VandenBerg, A, 2019
)
0.51
"3 years; range, 53-69 years) with persistent depression despite adequate antidepressant treatment (current DSM-IV-TR major depressive episode per the Structured Clinical Interview for DSM-IV-TR, Montgomery-Asberg Depression Rating Scale [MADRS] score ≥ 16, and treated with an adequately dosed antidepressant for ≥ 6 weeks) were studied from December 2016 to April 2018."( Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women: A Pilot Study.
Cusin, C; Dichtel, LE; Dording, C; Fava, M; Fisher, LB; Kimball, AS; Miller, KK; Mischoulon, D; Nyer, M; Pedrelli, P; Rao, EM; Shapero, BG, 2020
)
0.56
" Experience with the medication and further research is needed to clarify whether the current recommended dosing regimen is required for efficacy."( Evaluating brexanolone for the treatment of postpartum depression.
Payne, JL, 2021
)
0.62
" Further studies optimising target mechanisms and dosing are warranted."( Neurosteroid-based intervention using Ganaxolone and Emapunil for improving stress-induced myelination deficits and neurobehavioural disorders.
Crombie, GK; Hirst, JJ; Hodgson, DM; Palliser, HK; Shaw, JC; Walker, DW, 2021
)
0.62
" This study's objective was to determine the appropriate dosing for IV ganaxolone in RSE and obtain a preliminary assessment of efficacy and safety."( Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open-label, dose-finding, phase 2 trial.
Aimetti, A; Gasior, M; Husain, AM; Ramsay, RE; Swisher, CB; Vaitkevicius, H, 2022
)
0.72
" There were three ganaxolone dosing cohorts: low, 500 mg/day; medium, 650 mg/day; and high, 713 mg/day."( Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open-label, dose-finding, phase 2 trial.
Aimetti, A; Gasior, M; Husain, AM; Ramsay, RE; Swisher, CB; Vaitkevicius, H, 2022
)
0.72
" The steroid structure was chemically altered to improve bioavailability and create an oral dosage form."( Neuroactive steroids - new possibilities in the treatment of postpartum depression.
Adamičková, A; Gažová, A; Hrubá, O; Massarová, P; Vranecová, K; Žigová, L, 2022
)
0.72
" Each dog received ALLO (1 mg/kg, IV), and after a washout period of 2 weeks, each dog was dosed with MDZ (0."( Tolerability and pharmacokinetics of intravenous allopregnanolone with and without midazolam pretreatment in two healthy dogs.
Aleman, M; Bruun, DA; Chen, YJ; Lein, PJ; Ma, B; Rogawski, MA; Smiley-Jewell, SM; Wu, CY; Zolkowska, D, 2023
)
1.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
intravenous anaestheticnull
sedativeA central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
3-hydroxy-5beta-pregnan-20-oneThe 5beta-stereoisomer of 3-hydroxypregnan-20-one.
3alpha-hydroxy steroidA 3-hydroxy steroid in which the 3-hydroxy substituent is in the alpha-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Steroid hormone precursor biosynthesis015

Protein Targets (45)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency1.51890.000221.22318,912.5098AID743036; AID743053
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency16.93010.000214.376460.0339AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency26.79300.000229.305416,493.5996AID743075; AID743077; AID743079; AID743091
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency12.96030.000323.4451159.6830AID743065; AID743067
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)IC50 (µMol)0.10100.00010.507510.0000AID242285; AID71982; AID71999; AID72151
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)IC50 (µMol)0.10100.00010.507510.0000AID242285; AID71982; AID71999; AID72151
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)IC50 (µMol)0.10100.00010.507510.0000AID242285; AID71982; AID71999; AID72151
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)IC50 (µMol)0.10100.00010.505710.0000AID242285; AID71982; AID71999; AID72151
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)IC50 (µMol)0.10100.00010.497310.0000AID242285; AID71982; AID71999; AID72151
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)0.10100.00010.507510.0000AID242285; AID71982; AID71999; AID72151
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)IC50 (µMol)0.10100.00010.498810.0000AID242285; AID71982; AID71999; AID72151
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)0.10100.00010.504610.0000AID242285; AID71982; AID71999; AID72151
Sodium- and chloride-dependent GABA transporter 1Rattus norvegicus (Norway rat)IC50 (µMol)0.11700.00132.22068.3000AID71999
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)0.10100.00010.507510.0000AID242285; AID71982; AID71999; AID72151
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)IC50 (µMol)0.10100.00010.507510.0000AID242285; AID71982; AID71999; AID72151
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)IC50 (µMol)0.10100.00010.507510.0000AID242285; AID71982; AID71999; AID72151
Sodium- and chloride-dependent GABA transporter 2Rattus norvegicus (Norway rat)IC50 (µMol)0.11700.00321.79008.3000AID71999
Sodium- and chloride-dependent GABA transporter 3Rattus norvegicus (Norway rat)IC50 (µMol)0.11700.00321.54318.3000AID71999
Sodium- and chloride-dependent betaine transporterRattus norvegicus (Norway rat)IC50 (µMol)0.11700.00321.54318.3000AID71999
Gamma-aminobutyric acid receptor subunit alpha-1Mus musculus (house mouse)IC50 (µMol)0.07100.00000.03690.0740AID72151
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)0.10100.00010.506510.0000AID242285; AID71982; AID71999; AID72151
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)0.10100.00010.505710.0000AID242285; AID71982; AID71999; AID72151
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)0.10100.00010.507510.0000AID242285; AID71982; AID71999; AID72151
GABA theta subunitRattus norvegicus (Norway rat)IC50 (µMol)0.10100.00010.507510.0000AID242285; AID71982; AID71999; AID72151
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)IC50 (µMol)0.10100.00010.507510.0000AID242285; AID71982; AID71999; AID72151
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid Mus musculus (house mouse)EC50 (µMol)1.17490.87101.02291.1749AID265566
Gamma-aminobutyric acid receptor subunit alpha-6Mus musculus (house mouse)EC50 (µMol)1.17490.87101.02291.1749AID265566
Gamma-aminobutyric acid receptor subunit gamma-2Mus musculus (house mouse)EC50 (µMol)1.17490.87101.02291.1749AID265566
Gamma-aminobutyric acid receptor subunit deltaMus musculus (house mouse)EC50 (µMol)1.17490.87101.02291.1749AID265566
Gamma-aminobutyric acid receptor subunit alpha-2Mus musculus (house mouse)EC50 (µMol)1.17490.87101.02291.1749AID265566
Gamma-aminobutyric acid receptor subunit alpha-3Mus musculus (house mouse)EC50 (µMol)1.17490.87101.02291.1749AID265566
Gamma-aminobutyric acid receptor subunit gamma-3Mus musculus (house mouse)EC50 (µMol)1.17490.87101.02291.1749AID265566
Gamma-aminobutyric acid receptor subunit beta-1Mus musculus (house mouse)EC50 (µMol)1.17490.87101.02291.1749AID265566
Gamma-aminobutyric acid receptor subunit alpha-1Mus musculus (house mouse)EC50 (µMol)1.17490.87101.02291.1749AID265566
Gamma-aminobutyric acid receptor subunit beta-3Mus musculus (house mouse)EC50 (µMol)1.17490.87101.02291.1749AID265566
Gamma-aminobutyric acid receptor subunit alpha-5Mus musculus (house mouse)EC50 (µMol)1.17490.87101.02291.1749AID265566
Gamma-aminobutyric acid receptor subunit piMus musculus (house mouse)EC50 (µMol)1.17490.87101.02291.1749AID265566
Gamma-aminobutyric acid receptor subunit alpha-4Mus musculus (house mouse)EC50 (µMol)1.17490.87101.02291.1749AID265566
Gamma-aminobutyric acid receptor subunit thetaMus musculus (house mouse)EC50 (µMol)1.17490.87101.02291.1749AID265566
Gamma-aminobutyric acid receptor subunit gamma-1Mus musculus (house mouse)EC50 (µMol)1.17490.87101.02291.1749AID265566
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)POT0.11500.10500.64402.0000AID52291
Gamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)POT0.11500.10500.64402.0000AID52291
Gamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)POT0.11500.10500.64402.0000AID52291
Gamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)POT0.11500.10500.64402.0000AID52291
Gamma-aminobutyric acid receptor subunit alpha-4Bos taurus (cattle)POT0.11500.10500.64402.0000AID52291
Gamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)POT0.11500.10500.64402.0000AID52291
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
monoatomic ion transportGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)
cellular response to histamineGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
ligand-gated monoatomic ion channel activityGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
postsynaptic membraneGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-4Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-4Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (85)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID265566Increase in [3H]flunitrazepam binding to GABA-A receptor in mouse embryo cortical neurons2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Activity of B-nor analogues of neurosteroids on the GABA(A) receptor in primary neuronal cultures.
AID1069338Inhibition of VGLUT in rat brain assessed as [3H]-L-Glu uptake into synaptic vesicles at 250 uM relative to control2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
The development of benzo- and naphtho-fused quinoline-2,4-dicarboxylic acids as vesicular glutamate transporter (VGLUT) inhibitors reveals a possible role for neuroactive steroids.
AID501489Ratio of Kcat/Km for human recombinant AKR1C1 Leu308Val mutant to Kcat/Km for human recombinant wild type AKR1C12010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Factorizing the role of a critical leucine residue in the binding of substrate to human 20alpha-hydroxysteroid dehydrogenase (AKR1C1): molecular modeling and kinetic studies of the Leu308Val mutant enzyme.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID501483Activity at human recombinant AKR1C1 Leu308Val mutant expressed in Escherichia coli JM109 after 15 mins2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Factorizing the role of a critical leucine residue in the binding of substrate to human 20alpha-hydroxysteroid dehydrogenase (AKR1C1): molecular modeling and kinetic studies of the Leu308Val mutant enzyme.
AID72143In vitro current effect against rat GABA receptor alpha-1-beta-2-gamma-2 subunits expressed in Xenopus laevis oocytes at 1 uM (ratio +/- compound)2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Neurosteroid analogues. 9. Conformationally constrained pregnanes: structure-activity studies of 13,24-cyclo-18,21-dinorcholane analogues of the GABA modulatory and anesthetic steroids (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID382399Activity at rat GABAA alpha-1-beta-2-gamma-2L receptor expressed in Xenopus laevis assessed as ratio of current in drug-treated to GABA-treated oocyte at 10 uM by electrophysiology2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Neurosteroid analogues. 12. Potent enhancement of GABA-mediated chloride currents at GABAA receptors by ent-androgens.
AID266560Loss of swimming reflex in Xenopus laevis tadpole2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes.
AID72149Non-competitive displacement of [35S]TBPS from picrotoxin binding site found in heterogeneous Gamma-aminobutyric acid A receptor in rat brain membranes.2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Neurosteroid analogues. 9. Conformationally constrained pregnanes: structure-activity studies of 13,24-cyclo-18,21-dinorcholane analogues of the GABA modulatory and anesthetic steroids (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID196544Percent of maximal extent of inhibition was calculated by fitting [35S]TBPS inhibition data to a sigmoid function (rat brain cortical P2 membranes).1997Journal of medicinal chemistry, Jan-03, Volume: 40, Issue:1
Synthesis and in vitro activity of 3 beta-substituted-3 alpha-hydroxypregnan-20-ones: allosteric modulators of the GABAA receptor.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID501484Ratio of kcat/km for human recombinant AKR1C1 Leu308Val mutant expressed in Escherichia coli JM109 after 15 mins2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Factorizing the role of a critical leucine residue in the binding of substrate to human 20alpha-hydroxysteroid dehydrogenase (AKR1C1): molecular modeling and kinetic studies of the Leu308Val mutant enzyme.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID382392Anesthetic effect in Xenopus laevis assessed as loss of righting response2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Neurosteroid analogues. 12. Potent enhancement of GABA-mediated chloride currents at GABAA receptors by ent-androgens.
AID197261Compound was evaluated at 10 uM for its ability to initiate (gate) a current in the absence of GABA in cultured postnatal rat hippocampal neurons1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Neurosteroid analogues. 4. The effect of methyl substitution at the C-5 and C-10 positions of neurosteroids on electrophysiological activity at GABAA receptors.
AID266555Activity at rat GABA-Aalpha1 receptor plus beta-2-gamma-2L expressed in Xenopus laevis oocyte assessed as ratio of GABA-mediated current in presence to absence of compound at 0.1 uM2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID266558Activity at rat GABA-Aalpha1 receptor plus beta-2-gamma-2L expressed in Xenopus laevis oocyte assessed as ratio of GABA-mediated current in presence to absence of GABA at 10 uM2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID167990Electrophysiological effect on rat alpha-1-beta-2-gamma-2 GABA-A receptor subunits expressed in xenopus laevis oocytes at 1 uM2000Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17
Neurosteroid analogues. 8. Structure-activity studies of N-acylated 17a-aza-D-homosteroid analogues of the anesthetic steroids (3alpha, 5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID382391Displacement of [35S]TPBS from GABAA receptor in rat brain2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Neurosteroid analogues. 12. Potent enhancement of GABA-mediated chloride currents at GABAA receptors by ent-androgens.
AID246863Dose required for measuring loss of swimming reflex (LSR) in Xenopus laevis tadpoles2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID72140In vitro current effect against rat GABA receptor alpha-1-beta-2-gamma-2 subunits expressed in Xenopus laevis oocytes at 0.1 uM (ratio +/- compound)2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Neurosteroid analogues. 9. Conformationally constrained pregnanes: structure-activity studies of 13,24-cyclo-18,21-dinorcholane analogues of the GABA modulatory and anesthetic steroids (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID501485Ratio of Km for human recombinant AKR1C1 Leu308Val mutant to Km for human recombinant wild type AKR1C12010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Factorizing the role of a critical leucine residue in the binding of substrate to human 20alpha-hydroxysteroid dehydrogenase (AKR1C1): molecular modeling and kinetic studies of the Leu308Val mutant enzyme.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID266559Loss of righting reflex in Xenopus laevis tadpole2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes.
AID233476Hill coefficient for displacement of [35S]TBPS.2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Neurosteroid analogues. 9. Conformationally constrained pregnanes: structure-activity studies of 13,24-cyclo-18,21-dinorcholane analogues of the GABA modulatory and anesthetic steroids (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID243131Ratio of currents mediated by rat Alpha-1-beta-2-gamma-2L GABA-A receptor expressed in Xenopus oocytes at 10 uM in the absence of GABA2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID266554Displacement of [35S]TBPS from GABA-A receptor in rat brain membrane2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID382397Activity at rat GABAA alpha-1-beta-2-gamma-2L receptor expressed in Xenopus laevis expressed in assessed as ratio of current in treated to non-treated oocyte at 1 uM by electrophysiology2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Neurosteroid analogues. 12. Potent enhancement of GABA-mediated chloride currents at GABAA receptors by ent-androgens.
AID266557Activity at rat GABA-Aalpha1 receptor plus beta-2-gamma-2L expressed in Xenopus laevis oocyte assessed as ratio of GABA-mediated current in presence to absence of compound at 10 uM2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes.
AID197264Compound was evaluated at 10 uM GABA-mediated current in cultured postnatal rat hippocampal neurons1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Neurosteroid analogues. 4. The effect of methyl substitution at the C-5 and C-10 positions of neurosteroids on electrophysiological activity at GABAA receptors.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID243127Ratio of currents mediated by rat Alpha-1-beta-2-gamma-2L GABA-A receptor expressed in Xenopus oocytes at 0.1 uM in presence of 2 uM GABA2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID167989Electrophysiological effect on rat alpha-1-beta-2-gamma-2 GABA-A receptor subunits expressed in xenopus laevis oocytes at 10 uM in the absence of GABA2000Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17
Neurosteroid analogues. 8. Structure-activity studies of N-acylated 17a-aza-D-homosteroid analogues of the anesthetic steroids (3alpha, 5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID501482Ratio of kcat/km for human recombinant wild type AKR1C1 expressed in Escherichia coli JM109 after 15 mins2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Factorizing the role of a critical leucine residue in the binding of substrate to human 20alpha-hydroxysteroid dehydrogenase (AKR1C1): molecular modeling and kinetic studies of the Leu308Val mutant enzyme.
AID233478Hill coefficient for loss of swimming response.2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Neurosteroid analogues. 9. Conformationally constrained pregnanes: structure-activity studies of 13,24-cyclo-18,21-dinorcholane analogues of the GABA modulatory and anesthetic steroids (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID243126Ratio of currents mediated by rat Alpha-1-beta-2-gamma-2L GABA-A receptor expressed in Xenopus oocytes at 10 uM in presence of 2 uM GABA2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID72151Displacement of [3S]-tert-butylbicyclophosphorothionate (TBPS) from Gamma-aminobutyric acid A (GABA-A) receptor of rat brain membranes2000Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17
Neurosteroid analogues. 8. Structure-activity studies of N-acylated 17a-aza-D-homosteroid analogues of the anesthetic steroids (3alpha, 5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID52291Concentration required to potentiate GABA-evoked currents in voltage-clamped bovine chromaffin cells by 300%1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anesthetic activity of novel water-soluble 2 beta-morpholinyl steroids and their modulatory effects at GABAA receptors.
AID266556Activity at rat GABA-Aalpha1 receptor plus beta2gamma2L expressed in Xenopus laevis oocyte assessed as ratio of GABA-mediated current in presence to absence of compound at 1 uM2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes.
AID324687Displacement of [3H]TBOB from GABAA receptor in Sprague-Dawley rat cerebral cortex2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis and GABA(A) receptor activity of oxygen-bridged neurosteroid analogs.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID219900Loss of righting reflex in Xenopus laevis tadpole.2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Neurosteroid analogues. 9. Conformationally constrained pregnanes: structure-activity studies of 13,24-cyclo-18,21-dinorcholane analogues of the GABA modulatory and anesthetic steroids (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID265567Effect on GABA-A-induced 36chloride ion influx in mouse embryo cortical neurons at 10 uM relative to basal value2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Activity of B-nor analogues of neurosteroids on the GABA(A) receptor in primary neuronal cultures.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID71982Inhibition of binding of tert-butyl bicyclophosphorothionate ([35 S]TBPS) at Gamma-aminobutyric acid A receptor from rat whole brain membranes2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Conformationally constrained anesthetic steroids that modulate GABA(A) receptors.
AID119225Effect on interval between loss of righting reflex and return to righting reflex (sleep duration) was measured at a dose twice that of hypnotic dose.1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anesthetic activity of novel water-soluble 2 beta-morpholinyl steroids and their modulatory effects at GABAA receptors.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID242285Displacement of [35S]TBPS from picrotoxin site of GABA-A receptor of rat brain membranes2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID382396Activity at rat GABAA alpha-1-beta-2-gamma-2L receptor expressed in Xenopus laevis assessed as ratio of current in treated to non-treated oocyte at 0.1 uM by electrophysiology2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Neurosteroid analogues. 12. Potent enhancement of GABA-mediated chloride currents at GABAA receptors by ent-androgens.
AID246875Dose required for measuring the loss of righting reflex (LRR) in Xenopus laevis tadpoles2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID233477Hill coefficient for loss of righting response.2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Neurosteroid analogues. 9. Conformationally constrained pregnanes: structure-activity studies of 13,24-cyclo-18,21-dinorcholane analogues of the GABA modulatory and anesthetic steroids (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID167991Electrophysiological effect on rat alpha-1-beta-2-gamma-2 GABA-A receptor subunits expressed in xenopus laevis oocytes at 0.1 uM2000Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17
Neurosteroid analogues. 8. Structure-activity studies of N-acylated 17a-aza-D-homosteroid analogues of the anesthetic steroids (3alpha, 5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID501481Activity at human recombinant wild type AKR1C1 expressed in Escherichia coli JM109 after 15 mins2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Factorizing the role of a critical leucine residue in the binding of substrate to human 20alpha-hydroxysteroid dehydrogenase (AKR1C1): molecular modeling and kinetic studies of the Leu308Val mutant enzyme.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID71698Allosteric modulation of [35S]TBPS binding to Gamma-aminobutyric acid A receptor in rat brain cortical P2 membranes (inhibits binding with two components)1997Journal of medicinal chemistry, Jan-03, Volume: 40, Issue:1
Synthesis and in vitro activity of 3 beta-substituted-3 alpha-hydroxypregnan-20-ones: allosteric modulators of the GABAA receptor.
AID382394Anesthetic effect in Xenopus laevis assessed as loss of swimming response2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Neurosteroid analogues. 12. Potent enhancement of GABA-mediated chloride currents at GABAA receptors by ent-androgens.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID382398Activity at rat GABAA alpha-1-beta-2-gamma-2L receptor expressed in Xenopus laevis expressed in assessed as ratio of current in treated to non-treated oocyte at 10 uM by electrophysiology2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Neurosteroid analogues. 12. Potent enhancement of GABA-mediated chloride currents at GABAA receptors by ent-androgens.
AID167988Electrophysiological effect on rat alpha-1-beta-2-gamma-2 GABA-A receptor subunits expressed in xenopus laevis oocytes at 10 uM2000Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17
Neurosteroid analogues. 8. Structure-activity studies of N-acylated 17a-aza-D-homosteroid analogues of the anesthetic steroids (3alpha, 5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID243128Ratio of currents mediated by rat Alpha-1-beta-2-gamma-2L GABA-A receptor expressed in Xenopus oocytes at 1.0 uM in presence of 2 uM GABA2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID72142In vitro direct current effect against rat GABA receptor alpha-1-beta-2-gamma-2 subunits expressed in Xenopus laevis oocytes at 10 uM (ratio +/- compound, without GABA)2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Neurosteroid analogues. 9. Conformationally constrained pregnanes: structure-activity studies of 13,24-cyclo-18,21-dinorcholane analogues of the GABA modulatory and anesthetic steroids (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID221372Hypnotic dose required to cause a loss of righting reflex for a minimum period of 30 s in 50 percent of treated mice after intravenous administration.2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Conformationally constrained anesthetic steroids that modulate GABA(A) receptors.
AID114282Hypnotic dose was determined by observing loss of righting reflex for a minimum period of 30 sec in 50% of treated mice after i.v. administration.1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anesthetic activity of novel water-soluble 2 beta-morpholinyl steroids and their modulatory effects at GABAA receptors.
AID72141In vitro current effect against rat GABA receptor alpha-1-beta-2-gamma-2 subunits expressed in Xenopus laevis oocytes at 10 uM (ratio +/- compound)2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Neurosteroid analogues. 9. Conformationally constrained pregnanes: structure-activity studies of 13,24-cyclo-18,21-dinorcholane analogues of the GABA modulatory and anesthetic steroids (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID71999The concentration required to inhibit 50% of binding of [35S]TBPS to Gamma-aminobutyric acid A receptor to rat whole brain membranes.1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anesthetic activity of novel water-soluble 2 beta-morpholinyl steroids and their modulatory effects at GABAA receptors.
AID219901Loss of swimming behavior in Xenopus laevis tadpole.2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Neurosteroid analogues. 9. Conformationally constrained pregnanes: structure-activity studies of 13,24-cyclo-18,21-dinorcholane analogues of the GABA modulatory and anesthetic steroids (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,936)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990163 (8.42)18.7374
1990's393 (20.30)18.2507
2000's660 (34.09)29.6817
2010's523 (27.01)24.3611
2020's197 (10.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.60 (24.57)
Research Supply Index7.65 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index61.55 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (22.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials111 (5.59%)5.53%
Reviews187 (9.43%)6.00%
Case Studies6 (0.30%)4.05%
Observational1 (0.05%)0.25%
Other1,679 (84.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (19)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Expanded Access Protocol of ZULRESSO for Adult Patients With Postpartum Depression [NCT03924492]0 participants Expanded AccessApproved for marketing
A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19 [NCT04537806]Phase 329 participants (Actual)Interventional2020-12-18Terminated(stopped due to Internal company decision)
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-547 Injection in the Treatment of Adult Female Subjects With Severe Postpartum Depression and Adult Female Subj [NCT02942004]Phase 3138 participants (Actual)Interventional2016-08-01Completed
A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study Investigating Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD) [NCT03697265]Phase 2475 participants (Actual)Interventional2018-04-20Completed
Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase 1 [NCT02221622]Phase 124 participants (Actual)Interventional2014-08-31Completed
An Exploratory Phase II, Randomised, Double-blind, Placebo-controlled, Parallel-group Study Investigating the Efficacy and Safety of Sepranolone in Women With Menstrual Migraine [NCT04102995]Phase 286 participants (Actual)Interventional2019-08-27Completed
Effect of Allopregnanolone on Stress-induced Craving [NCT04015869]Phase 116 participants (Actual)Interventional2019-07-01Completed
An Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Brexanolone in the Treatment of Adult Participants With Tinnitus [NCT05645432]Phase 210 participants (Actual)Interventional2023-05-10Completed
A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy Followed by Long-term Open-label Treatment. [NCT03865732]Phase 229 participants (Actual)Interventional2019-05-17Completed
Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: IV to IM Bridging Study [NCT03748303]Phase 112 participants (Anticipated)Interventional2019-10-01Active, not recruiting
Safety and Efficacy of Allopregnanolone (Allo) as a Regenerative Therapeutic for Alzheimer's Disease: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Clinical Trial [NCT04838301]Phase 2200 participants (Anticipated)Interventional2023-08-15Recruiting
Assessment of Safe-use Conditions for Administration of ZULRESSO in a Home Setting [NCT05059600]Phase 452 participants (Actual)Interventional2021-10-08Completed
Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD [NCT04468360]Phase 2256 participants (Anticipated)Interventional2022-03-04Recruiting
Novel Regenerative Therapeutic in Chronic Complex TBI [NCT04003285]Phase 2132 participants (Anticipated)Interventional2024-03-01Not yet recruiting
A Randomized, Open-label, Multicenter, Phase 2 Clinical Trial to Explore the Safety and Efficacy of Sepranolone in Pediatric and Adult Patients With Tourette Syndrome [NCT05434546]Phase 226 participants (Actual)Interventional2022-02-16Completed
A Double-blind, Placebo-controlled, Randomized Clinical Trial of Allopregnanolone for the Treatment of Traumatic Brain Injury [NCT01673828]Phase 213 participants (Actual)Interventional2013-04-30Completed
Using Allopregnanolone to Probe Behavioral and Neurobiological Mechanisms That Underlie Depression in Women During the Perimenopause [NCT05329779]Phase 480 participants (Anticipated)Interventional2022-11-04Recruiting
Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone [NCT02603926]Phase 26 participants (Actual)Interventional2015-10-31Completed
A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults With Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed by Long-term Open-label Treatment [NCT03572933]Phase 3101 participants (Actual)Interventional2018-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01673828 (1) [back to overview]Extended Glasgow Outcome Scale (GOS-E) Score
NCT02603926 (4) [back to overview]Behavioral Dyscontrol Scale - 2 (BDS-2) Total Score
NCT02603926 (4) [back to overview]California Verbal Learning Test II (CVLT2) Trial 1-5 Free Recall Total Raw Score
NCT02603926 (4) [back to overview]CATSYS Dot-to-Dot Tremor Intensity (CATSYS DTD TI)
NCT02603926 (4) [back to overview]Hippocampal Volume, as Measured by Structural MRI
NCT02942004 (13) [back to overview]Change From Baseline at 60 Hours in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score
NCT02942004 (13) [back to overview]Change From Baseline in HAM-D Total Score at Day 30
NCT02942004 (13) [back to overview]Percentage of Participants With Treatment-Emergent Adverse Events
NCT02942004 (13) [back to overview]Change From Baseline at Key Time Points in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
NCT02942004 (13) [back to overview]Change From Baseline in HAM-D Bech 6 Subscale
NCT02942004 (13) [back to overview]Change From Baseline in HAM-D Individual Item Scores
NCT02942004 (13) [back to overview]Change From Baseline in HAM-D Total Score
NCT02942004 (13) [back to overview]Change From Baseline in the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score
NCT02942004 (13) [back to overview]Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response
NCT02942004 (13) [back to overview]Percentage of Participants With HAM-D Remission
NCT02942004 (13) [back to overview]Percentage of Participants With HAM-D Response
NCT02942004 (13) [back to overview]Time to Change in Antidepressant Medication
NCT02942004 (13) [back to overview]Time to Change in Antidepressant Medication
NCT03572933 (8) [back to overview]Summary of 28-day Seizure Frequency for Major Motor Seizure Types
NCT03572933 (8) [back to overview]Arithmetic Change in Longest Seizure Free Interval, Based on Primary Seizure Types
NCT03572933 (8) [back to overview]Caregiver Global Impression of Change in Attention
NCT03572933 (8) [back to overview]Caregiver Global Impression of Change in Seizure Intensity and Duration
NCT03572933 (8) [back to overview]Caregiver Global Impression of Change in Target Behavior
NCT03572933 (8) [back to overview]Clinical Global Impression of Improvement - Clinician
NCT03572933 (8) [back to overview]Clinical Global Impression of Improvement - Parent/Caregiver
NCT03572933 (8) [back to overview]Percentage of Seizure-free Days for Major Motor Seizure Types
NCT03865732 (3) [back to overview]Summary of 28-day Seizure Frequency for Subjects in the Biomarker-positive Stratum (Median Percent Change)
NCT03865732 (3) [back to overview]Summary of 28-day Seizure Frequency Through 17 Week Post-Baseline Phase (Median Percent Change)
NCT03865732 (3) [back to overview]50% Primary Seizure Reduction
NCT04537806 (3) [back to overview]Percentage of Participants Who Are Alive and Free of Respiratory Failure at Day 28
NCT04537806 (3) [back to overview]Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)
NCT04537806 (3) [back to overview]Number of Participants Who Died Through Day 28
NCT05059600 (5) [back to overview]Number of Use-Related Issues Related to the Home Administration of ZULRESSO®
NCT05059600 (5) [back to overview]Percentage of Participants With Medication Error
NCT05059600 (5) [back to overview]Percentage of Participants With At Least One Treatment-Emergent Adverse Event (TEAE) Leading to Dose Interruption/Discontinuation
NCT05059600 (5) [back to overview]Percentage of Participants With Nonadherence With the Safe-Use Conditions for Administration of ZULRESSO®
NCT05059600 (5) [back to overview]Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

Extended Glasgow Outcome Scale (GOS-E) Score

GOS-E is a global scale for functional outcome that rates patient status into one of 8 levels. The minimum score is 1 and the maximum score is 8. 1 = dead; 2 = vegetative state; 3 = low severe disability; 4 = upper severe disability; 5 = low moderate disability; 6 = upper moderate disability; 7 = low good recovery; 8 = upper good recovery. GOS-E was assessed by 19 question structured interview. (NCT01673828)
Timeframe: 6 months after injury

InterventionGOS-E Score (Mean)
Allopregnanolone4.2
Placebo4.3

[back to top]

Behavioral Dyscontrol Scale - 2 (BDS-2) Total Score

The BDS-2 is a validated 9-item assessment measuring the ability to regulate purposeful, goal-directed activity and to engage in activities of daily living, with focus on motor items. Each of the 9 items is scored on a scale of 0 to 3, resulting in a summed total score ranging from 0 to 27. Higher scores reflect fewer errors and stronger ability to regulate motor activities. Mean and standard deviation for total score at baseline/pre-treatment and at 14 weeks/post-treatment are presented here. (NCT02603926)
Timeframe: Baseline/pre-treatment and 14 weeks/post-treatment

Interventionscore on a scale (Mean)
Baseline/Pre-Treatment14 Weeks/Post-Treatment
Allopregnanolone12.715.3

[back to top]

California Verbal Learning Test II (CVLT2) Trial 1-5 Free Recall Total Raw Score

California Verbal Learning Test II (CVLT2) is an assessment measuring working memory. Trials 1-5 measure the total number of words remembered after 5 repeated trials and are summed to generate a raw score (called Trial 1-5 Free Recall Total Raw Score) ranging from 0 to 80, with higher scores reflecting better working memory. Mean and standard deviation for raw score at baseline/pre-treatment and at 14 weeks/post-treatment are presented here. (NCT02603926)
Timeframe: Baseline/pre-treatment and 14 weeks/post-treatment

Interventionscore on a scale (Mean)
Baseline/Pre-Treatment14 Weeks/Post-Treatment
Allopregnanolone34.033.5

[back to top]

CATSYS Dot-to-Dot Tremor Intensity (CATSYS DTD TI)

The CATSYS system is a portable device recording various measures of neuromotor control, including tremor. The CATSYS Dot-to-Dot Tremor Intensity (DTD TI) protocol quantifies tremor by having a participant hold a tremor pen as they would an ordinary pen, with the elbow joint bent at a right angle and free of body contact, and the pen positioned approximately 4 inches from the navel. Subjects are instructed to use the pen first to tap the center of two circular stickers, approximately 0.5 inch in diameter, placed on opposite ends of the bottom portion of the computer monitor; then, subjects are instructed to trace a line across the table using the tremor pen. The pen is connected to a computer with sensors that measure tremor intensity (TI) in units of meters per second (m/s). Larger values reflect greater tremor intensity. Mean right-hand and left-hand TI and standard deviation at baseline/pre-treatment and at 14 weeks/post-treatment are reported here. (NCT02603926)
Timeframe: Baseline/pre-treatment and 14 weeks/post-treatment

Interventionmeters per second (m/s) (Mean)
Baseline/Pre-Treatment, Right-HandBaseline/Pre-Treatment, Left-Hand14 Weeks/Post-Treatment, Right-Hand14 Weeks/Post-Treatment, Left-Hand
Allopregnanolone0.870.740.790.65

[back to top]

Hippocampal Volume, as Measured by Structural MRI

Patients will undergo structural Magnetic Resonance Imaging (MRI) at baseline/pre-treatment and at 14 weeks/post-treatment. The MRI is interpreted by a trained clinician and hippocampal volume in cubic centimeters is measured and recorded. Larger values reflect greater volumes of the hippocampus, and greater hippocampal volume post-treatment may be indicative of increased neurogenesis. Mean hippocampal volume and standard deviation at baseline/pre-treatment and post-treatment is reported here. (NCT02603926)
Timeframe: Baseline/pre-treatment and 14 weeks/post-treatment

Interventioncubic centimeters (Mean)
Baseline/Pre-Treatment14 Weeks/Post-Treatment
Allopregnanolone5.875.84

[back to top]

Change From Baseline at 60 Hours in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score

The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. (NCT02942004)
Timeframe: Baseline, Hour 60

Interventionscore on a scale (Least Squares Mean)
Placebo-14.04
SAGE-547 60 μg/kg/h-19.54
SAGE-547 90 μg/kg/h-17.72

[back to top]

Change From Baseline in HAM-D Total Score at Day 30

The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. (NCT02942004)
Timeframe: Baseline, Day 30

Interventionscore on a scale (Least Squares Mean)
Placebo-13.82
SAGE-547 60 μg/kg/h-19.45
SAGE-547 90 μg/kg/h-17.62

[back to top]

Percentage of Participants With Treatment-Emergent Adverse Events

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent AE (TEAE) is defined as an AE with onset on or after the start of study drug infusion, or any worsening of a pre-existing medical condition/AE with onset on or after the start of study drug infusion. (NCT02942004)
Timeframe: Up to approximately 37 days.

Interventionpercentage of participants (Number)
Placebo51.2
SAGE-547 60 μg/kg/h50.0
SAGE-547 90 μg/kg/h53.7

[back to top]

Change From Baseline at Key Time Points in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in participants with mood disorders. It was designed as an adjunct to the HAM-D, to be more sensitive than the Hamilton Scale to the changes brought on by antidepressants and other forms of treatment. Each item yielded a score of 0 to 6. The MADRS total score was calculated as the sum of the 10 individual item scores, which ranged from 0 to 60. Higher MADRS scores indicates more severe depression. A negative change from baseline indicates less severe depression. A positive change from baseline indicates more severe depression. (NCT02942004)
Timeframe: Baseline, Hour 60, Days 7 and 30

,,
Interventionscore on a scale (Least Squares Mean)
Hour 60Day 7Day 30
Placebo-19.98-19.01-19.43
SAGE-547 60 μg/kg/h-26.84-23.31-25.06
SAGE-547 90 μg/kg/h-24.19-20.32-23.02

[back to top]

Change From Baseline in HAM-D Bech 6 Subscale

The HAM-D Bech 6 subscale score is calculated as the sum of the following six items: Item # 1 (depressed mood), Item # 2 (feelings of guilt), Item # 7 (work and activities), Item # 8 (retardation), Item # 10 (anxiety psychic), and Item # 13 (general somatic symptoms). Each item is scored in a range of 0 to 2 or 0 to 4, with higher scores indicating a greater degree of depression. The scores were transformed to a 100-point scale with a higher score indicating a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. (NCT02942004)
Timeframe: Baseline, Hour 60, Days 7 and 30

,,
Interventionscore on a scale (Least Squares Mean)
Hour 60Day 7Day 30
Placebo-32.60-29.43-30.94
SAGE-547 60 μg/kg/h-44.67-38.52-42.62
SAGE-547 90 μg/kg/h-38.49-31.67-39.20

[back to top]

Change From Baseline in HAM-D Individual Item Scores

The HAM-D comprises individual ratings of the following symptoms scored in a range of 0 to 2: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following symptoms are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. (NCT02942004)
Timeframe: Baseline, Hour 2, Hour 4, Hour 8, Hour 12, Hour 24, Hour 36, Hour 48, Hour 60, Hour 72 and Days 7, 14, 21 and 30

,,
Interventionscore on a scale (Least Squares Mean)
Depressed Mood, Change at Hour 2Depressed Mood, Change at Hour 4Depressed Mood, Change at Hour 8Depressed Mood, Change at Hour 12Depressed Mood, Change at Hour 24Depressed Mood, Change at Hour 36Depressed Mood, Change at Hour 48Depressed Mood, Change at Hour 60Depressed Mood, Change at Hour 72Depressed Mood, Change at Day 7Depressed Mood, Change at Day 14Depressed Mood, Change at Day 21Depressed Mood, Change at Day 30Feelings of Guilt, Change at Hour 2Feelings of Guilt, Change at Hour 4Feelings of Guilt, Change at Hour 8Feelings of Guilt, Change at Hour 12Feelings of Guilt, Change at Hour 24Feelings of Guilt, Change at Hour 36Feelings of Guilt, Change at Hour 48Feelings of Guilt, Change at Hour 60Feelings of Guilt, Change at Hour 72Feelings of Guilt, Change at Day 7Feelings of Guilt, Change at Day 14Feelings of Guilt, Change at Day 21Feelings of Guilt, Change at Day 30Suicide, Change at Hour 2Suicide, Change at Hour 4Suicide, Change at Hour 8Suicide, Change at Hour 12Suicide, Change at Hour 24Suicide, Change at Hour 36Suicide, Change at Hour 48Suicide, Change at Hour 60Suicide, Change at Hour 72Suicide, Change at Day 7Suicide, Change at Day 14Suicide, Change at Day 21Suicide, Change at Day 30Insomnia - Early, Change at Hour 2Insomnia - Early, Change at Hour 4Insomnia - Early, Change at Hour 8Insomnia - Early, Change at Hour 12Insomnia - Early, Change at Hour 24Insomnia - Early, Change at Hour 36Insomnia - Early, Change at Hour 48Insomnia - Early, Change at Hour 60Insomnia - Early, Change at Hour 72Insomnia - Early, Change at Day 7Insomnia - Early, Change at Day 14Insomnia - Early, Change at Day 21Insomnia - Early, Change at Day 30Insomnia - Middle, Change at Hour 2Insomnia - Middle, Change at Hour 4Insomnia - Middle, Change at Hour 8Insomnia - Middle, Change at Hour 12Insomnia - Middle, Change at Hour 24Insomnia - Middle, Change at Hour 36Insomnia - Middle, Change at Hour 48Insomnia - Middle, Change at Hour 60Insomnia - Middle, Change at Hour 72Insomnia - Middle, Change at Day 7Insomnia - Middle, Change at Day 14Insomnia - Middle, Change at Day 21Insomnia - Middle, Change at Day 30Insomnia - Late, Change at Hour 2Insomnia - Late, Change at Hour 4Insomnia - Late, Change at Hour 8Insomnia - Late, Change at Hour 12Insomnia - Late, Change at Hour 24Insomnia - Late, Change at Hour 36Insomnia - Late, Change at Hour 48Insomnia - Late, Change at Hour 60Insomnia - Late, Change at Hour 72Insomnia - Late, Change at Day 7Insomnia - Late, Change at Day 14Insomnia - Late, Change at Day 21Insomnia - Late, Change at Day 30Work and Activities, Change at Hour 2Work and Activities, Change at Hour 4Work and Activities, Change at Hour 8Work and Activities, Change at Hour 12Work and Activities, Change at Hour 24Work and Activities, Change at Hour 36Work and Activities, Change at Hour 48Work and Activities, Change at Hour 60Work and Activities, Change at Hour 72Work and Activities, Change at Day 7Work and Activities, Change at Day 14Work and Activities, Change at Day 21Work and Activities, Change at Day 30Retardation, Change at Hour 2Retardation, Change at Hour 4Retardation, Change at Hour 8Retardation, Change at Hour 12Retardation, Change at Hour 24Retardation, Change at Hour 36Retardation, Change at Hour 48Retardation, Change at Hour 60Retardation, Change at Hour 72Retardation, Change at Day 7Retardation, Change at Day 14Retardation, Change at Day 21Retardation, Change at Day 30Agitation, Change at Hour 2Agitation, Change at Hour 4Agitation, Change at Hour 8Agitation, Change at Hour 12Agitation, Change at Hour 24Agitation, Change at Hour 36Agitation, Change at Hour 48Agitation, Change at Hour 60Agitation, Change at Hour 72Agitation, Change at Day 7Agitation, Change at Day 14Agitation, Change at Day 21Agitation, Change at Day 30Anxiety Psychic, Change at Hour 2Anxiety Psychic, Change at Hour 4Anxiety Psychic, Change at Hour 8Anxiety Psychic, Change at Hour 12Anxiety Psychic, Change at Hour 24Anxiety Psychic, Change at Hour 36Anxiety Psychic, Change at Hour 48Anxiety Psychic, Change at Hour 60Anxiety Psychic, Change at Hour 72Anxiety Psychic, Change at Day 7Anxiety Psychic, Change at Day 14Anxiety Psychic, Change at Day 21Anxiety Psychic, Change at Day 30Anxiety Somatic, Change at Hour 2Anxiety Somatic, Change at Hour 4Anxiety Somatic, Change at Hour 8Anxiety Somatic, Change at Hour 12Anxiety Somatic, Change at Hour 24Anxiety Somatic, Change at Hour 36Anxiety Somatic, Change at Hour 48Anxiety Somatic, Change at Hour 60Anxiety Somatic, Change at Hour 72Anxiety Somatic, Change at Day 7Anxiety Somatic, Change at Day 14Anxiety Somatic, Change at Day 21Anxiety Somatic, Change at Day 30Somatic Symptoms GI, Change at Hour 2Somatic Symptoms GI, Change at Hour 4Somatic Symptoms GI, Change at Hour 8Somatic Symptoms GI, Change at Hour 12Somatic Symptoms GI, Change at Hour 24Somatic Symptoms GI, Change at Hour 36Somatic Symptoms GI, Change at Hour 48Somatic Symptoms GI, Change at Hour 60Somatic Symptoms GI, Change at Hour 72Somatic Symptoms GI, Change at Day 7Somatic Symptoms GI, Change at Day 14Somatic Symptoms GI, Change at Day 21Somatic Symptoms GI, Change at Day 30Somatic Symptoms General, Change at Hour 2Somatic Symptoms General, Change at Hour 4Somatic Symptoms General, Change at Hour 8Somatic Symptoms General, Change at Hour 12Somatic Symptoms General, Change at Hour 24Somatic Symptoms General, Change at Hour 36Somatic Symptoms General, Change at Hour 48Somatic Symptoms General, Change at Hour 60Somatic Symptoms General, Change at Hour 72Somatic Symptoms General, Change at Day 7Somatic Symptoms General, Change at Day 14Somatic Symptoms General, Change at Day 21Somatic Symptoms General, Change at Day 30Genital Symptoms, Change at Hour 2Genital Symptoms, Change at Hour 4Genital Symptoms, Change at Hour 8Genital Symptoms, Change at Hour 12Genital Symptoms, Change at Hour 24Genital Symptoms, Change at Hour 36Genital Symptoms, Change at Hour 48Genital Symptoms, Change at Hour 60Genital Symptoms, Change at Hour 72Genital Symptoms, Change at Day 7Genital Symptoms, Change at Day 14Genital Symptoms, Change at Day 21Genital Symptoms, Change at Day 30Hypochondriasis, Change at Hour 2Hypochondriasis, Change at Hour 4Hypochondriasis, Change at Hour 8Hypochondriasis, Change at Hour 12Hypochondriasis, Change at Hour 24Hypochondriasis, Change at Hour 36Hypochondriasis, Change at Hour 48Hypochondriasis, Change at Hour 60Hypochondriasis, Change at Hour 72Hypochondriasis, Change at Day 7Hypochondriasis, Change at Day 14Hypochondriasis, Change at Day 21Hypochondriasis, Change at Day 30Loss of Weight, Change at Hour 2Loss of Weight, Change at Hour 4Loss of Weight, Change at Hour 8Loss of Weight, Change at Hour 12Loss of Weight, Change at Hour 24Loss of Weight, Change at Hour 36Loss of Weight, Change at Hour 48Loss of Weight, Change at Hour 60Loss of Weight, Change at Hour 72Loss of Weight, Change at Day 7Loss of Weight, Change at Day 14Loss of Weight, Change at Day 21Loss of Weight, Change at Day 30Insight, Change at Hour 2Insight, Change at Hour 4Insight, Change at Hour 8Insight, Change at Hour 12Insight, Change at Hour 24Insight, Change at Hour 36Insight, Change at Hour 48Insight, Change at Hour 60Insight, Change at Hour 72Insight, Change at Day 7Insight, Change at Day 14Insight, Change at Day 21Insight, Change at Day 30
Placebo-0.54-0.79-1.02-1.33-1.40-1.47-1.58-1.56-1.75-1.49-1.53-1.48-1.53-0.46-0.70-0.84-1.04-1.04-1.23-1.25-1.23-1.42-1.18-1.33-1.10-1.40-0.57-0.64-0.81-0.92-0.87-0.90-0.88-0.81-0.88-0.71-0.92-0.61-0.76-0.27-0.29-0.29-0.22-0.47-0.55-0.76-0.85-0.57-0.69-0.97-0.69-0.67-0.13-0.16-0.20-0.16-0.57-0.74-0.90-0.83-0.93-0.95-0.72-0.77-0.78-0.16-0.16-0.14-0.16-0.68-0.75-0.89-0.89-1.07-0.89-0.79-0.77-0.77-0.30-0.51-0.81-1.02-1.07-1.39-1.51-1.46-1.67-1.39-1.58-1.35-1.55-0.18-0.34-0.36-0.57-0.48-0.71-0.57-0.76-0.67-0.67-0.74-0.72-0.66-0.46-0.56-0.51-0.56-0.54-0.63-0.74-0.58-0.65-0.60-0.87-0.61-0.64-0.60-0.90-1.25-1.39-1.16-1.37-1.41-1.48-1.55-1.25-1.42-1.17-1.15-0.56-0.86-0.79-0.86-0.77-0.86-0.86-1.00-0.91-0.91-0.70-0.94-0.80-0.28-0.28-0.42-0.51-0.47-0.54-0.61-0.82-0.68-0.63-0.77-0.70-0.82-0.23-0.27-0.27-0.51-0.60-0.64-0.67-0.78-0.81-0.62-0.64-0.55-0.660.000.00-0.07-0.07-0.16-0.23-0.35-0.35-0.32-0.51-0.49-0.68-0.82-0.23-0.32-0.23-0.32-0.39-0.39-0.49-0.49-0.60-0.49-0.54-0.84-0.60-0.05-0.07-0.07-0.09-0.07-0.14-0.05-0.09-0.14-0.30-0.43-0.49-0.24-0.01-0.01-0.03-0.030.04-0.03-0.03-0.06-0.06-0.06-0.03-0.10-0.01
SAGE-547 60 μg/kg/h-0.54-0.97-1.23-1.50-1.40-2.03-2.07-2.27-2.32-1.94-2.06-1.79-2.19-0.54-1.12-1.25-1.25-1.50-1.59-1.64-1.68-1.69-1.38-1.49-1.51-1.61-0.87-0.92-1.00-0.89-0.96-1.00-0.94-1.03-1.01-0.90-0.99-0.80-0.99-0.04-0.22-0.17-0.25-1.10-1.16-1.07-1.10-0.96-1.20-1.19-1.28-1.340.03-0.21-0.16-0.18-0.98-1.03-1.17-1.22-1.22-1.05-1.36-1.27-1.210.01-0.12-0.20-0.01-0.94-0.91-1.16-1.16-1.13-0.80-0.96-0.89-1.03-0.43-0.74-0.95-1.20-1.19-1.77-1.80-2.04-2.18-1.82-1.57-1.96-2.080.17-0.02-0.20-0.47-0.47-0.87-0.70-0.84-0.87-1.02-0.87-1.05-1.08-0.52-0.70-0.68-0.65-0.86-0.82-0.78-0.85-0.85-0.78-0.75-0.69-0.80-0.70-1.26-1.41-1.52-1.79-1.99-1.86-1.97-1.84-1.44-1.45-1.26-1.45-0.67-1.09-1.22-1.16-1.24-1.34-1.42-1.58-1.58-1.28-1.08-1.40-1.40-0.29-0.55-0.60-0.79-0.88-1.14-1.16-1.24-1.23-1.00-1.03-1.17-1.14-0.28-0.44-0.33-0.50-0.67-0.70-1.05-1.06-1.26-0.91-0.92-1.04-1.000.00-0.11-0.16-0.08-0.28-0.46-0.46-0.48-0.57-0.71-0.70-0.90-0.97-0.29-0.39-0.47-0.41-0.55-0.61-0.63-0.60-0.66-0.68-0.59-0.80-0.660.03-0.04-0.020.03-0.12-0.10-0.12-0.26-0.20-0.36-0.42-0.59-0.550.02-0.01-0.04-0.06-0.01-0.040.02-0.06-0.01-0.06-0.07-0.08-0.06
SAGE-547 90 μg/kg/h-0.45-0.79-0.94-1.15-1.47-1.49-1.84-1.92-1.97-1.55-1.65-1.75-1.97-0.40-0.84-0.94-0.76-1.03-1.26-1.60-1.63-1.57-1.36-1.56-1.51-1.62-0.48-0.61-0.63-0.66-0.68-0.75-0.95-0.98-0.90-0.77-0.80-0.88-0.88-0.19-0.29-0.36-0.26-0.87-0.84-1.27-1.19-0.91-0.97-1.06-1.11-1.09-0.17-0.24-0.32-0.22-0.93-1.02-1.19-1.23-1.09-0.87-0.98-0.90-0.99-0.22-0.34-0.37-0.31-0.95-0.90-1.15-1.22-1.12-1.04-0.86-0.74-1.09-0.25-0.43-0.67-0.83-1.04-1.09-1.57-1.70-1.67-1.57-1.60-1.87-1.93-0.01-0.03-0.16-0.42-0.47-0.65-0.60-0.74-0.80-0.70-0.77-0.81-0.91-0.45-0.52-0.55-0.59-0.69-0.74-0.78-0.70-0.82-0.66-0.82-0.76-0.62-0.76-1.12-1.22-1.35-1.59-1.41-1.71-1.64-1.61-1.30-1.17-1.34-1.43-0.75-0.88-1.05-0.91-1.12-1.08-1.20-1.31-1.29-0.98-0.88-1.05-0.99-0.30-0.44-0.57-0.56-0.79-0.78-0.84-0.96-1.01-0.66-0.89-0.91-0.91-0.14-0.33-0.28-0.49-0.55-0.79-0.90-0.95-1.00-0.61-0.59-0.72-0.95-0.16-0.13-0.16-0.24-0.28-0.51-0.63-0.67-0.72-0.79-0.83-0.87-0.95-0.34-0.34-0.41-0.44-0.48-0.49-0.58-0.59-0.55-0.58-0.51-0.57-0.600.060.01-0.04-0.09-0.24-0.19-0.26-0.35-0.26-0.60-0.64-0.61-0.480.020.040.040.070.04-0.010.02-0.09-0.06-0.03-0.09-0.09-0.08

[back to top]

Change From Baseline in HAM-D Total Score

The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. (NCT02942004)
Timeframe: Baseline, Hours 2, 4, 8, 12, 24, 36, 48, 72, and Days 7, 14, and 21

,,
Interventionscore on a scale (Least Squares Mean)
Change at Hour 2Change at Hour 4Change at Hour 8Change at Hour 12Change at Hour 24Change at Hour 36Change at Hour 48Change at Hour 72Change at Day 7Change at Day 14Change at Day 21
Placebo-5.04-6.88-8.13-9.79-10.71-12.58-13.55-14.67-13.34-14.64-13.23
SAGE-547 60 μg/kg/h-4.99-8.99-10.18-11.04-15.00-17.69-18.04-19.69-17.41-17.56-18.15
SAGE-547 90 μg/kg/h-4.89-7.18-8.50-9.07-13.03-13.93-16.89-17.19-14.93-15.64-16.74

[back to top]

Change From Baseline in the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score

"The GAD-7 is a participant-rated, generalized anxiety symptom severity scale. Scoring for GAD-7 generalized anxiety is calculated by assigning scores of 0 = not at all sure, 1 = several days, 2 = over half the days, and 3 = nearly every day to the response categories. The GAD-7 total score for the seven items ranges from 0 to 21, where a score of 0 to 4 = minimal anxiety, 5 to 9 = mild anxiety, 10 to 14 = moderate anxiety, and 15 to 21 = severe anxiety. The GAD-7 total score was calculated as the sum of the seven individual item scores. A negative change from baseline indicates less anxiety. A positive change from baseline indicates more anxiety." (NCT02942004)
Timeframe: Baseline, Hour 60, Days 7, 14, 21 and 30

,,
Interventionscore on a scale (Least Squares Mean)
Hour 60Day 7Day 14Day 21Day 30
Placebo-6.95-6.57-8.60-8.47-7.70
SAGE-547 60 μg/kg/h-8.08-9.13-9.20-8.53-9.72
SAGE-547 90 μg/kg/h-7.99-6.32-8.71-9.22-9.15

[back to top]

Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response

The CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I was only rated at post-treatment assessments. By definition, all CGI-I assessments were evaluated against baseline conditions. CGI-I response was defined as having a score of 1 (very much improved) or 2 (much improved). (NCT02942004)
Timeframe: Hour 60, Days 7 and 30

,,
Interventionpercentage of participants (Number)
Hour 60Day 7Day 30
Placebo55.846.552.4
SAGE-547 60 μg/kg/h83.871.180.0
SAGE-547 90 μg/kg/h82.164.172.2

[back to top]

Percentage of Participants With HAM-D Remission

The HAM-D remission is defined as having a HAM-D total score of ≤7. The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. (NCT02942004)
Timeframe: Hour 60, Days 7 and 30

,,
Interventionpercentage of participants (Number)
Hour 60Day 7Day 30
Placebo16.330.231.0
SAGE-547 60 μg/kg/h51.431.648.6
SAGE-547 90 μg/kg/h30.820.038.9

[back to top]

Percentage of Participants With HAM-D Response

The HAM-D response is defined as having a 50% or greater reduction from baseline in HAM-D total score. The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. (NCT02942004)
Timeframe: Hour 60, Days 7 and 30

,,
Interventionpercentage of participants (Number)
Hour 60Day 7Day 30
Placebo55.848.850.0
SAGE-547 60 μg/kg/h86.568.482.9
SAGE-547 90 μg/kg/h74.452.569.4

[back to top]

Time to Change in Antidepressant Medication

The time to first start or increase in the dose and time to first stop or decrease in the dose of any antidepressant medication. (NCT02942004)
Timeframe: Up to approximately 37 days.

Interventiondays (Median)
Time to first start/increase in dose
Placebo16

[back to top]

Time to Change in Antidepressant Medication

The time to first start or increase in the dose and time to first stop or decrease in the dose of any antidepressant medication. (NCT02942004)
Timeframe: Up to approximately 37 days.

,
Interventiondays (Median)
Time to first start/increase in doseTime to first stop/decrease in dose
SAGE-547 60 μg/kg/h1229
SAGE-547 90 μg/kg/h819

[back to top]

Summary of 28-day Seizure Frequency for Major Motor Seizure Types

"Summary of 28-day seizure frequency for Major Motor Seizure Types during the double-blind treatment period relative to the 6-week prospective baseline period~Note: Summaries are based on the sum of the individual seizures, the countable seizures, and the clusters with uncountable seizures (each cluster with uncountable seizures counts as 1 seizure). Within the baseline and post baseline intervals, 28-day seizure frequency was calculated as the total number of seizures in the interval divided by the number of days with available seizure data in the interval, multiplied by 28." (NCT03572933)
Timeframe: End of the double-blind 17 week treatment period

,
InterventionSeizures per day (Median)
Baseline (Median)17 week-post baseline phase (Median)
Ganaxolone54.0045.03
Placebo49.1755.50

[back to top]

Arithmetic Change in Longest Seizure Free Interval, Based on Primary Seizure Types

Arithmetic change in longest seizure free interval, based on primary seizure types during the double-blind treatment period of ganaxolone compared to placebo (NCT03572933)
Timeframe: End of the double-blind 17 week treatment period

Interventiondays (Mean)
Placebo-4.63
Ganaxolone-0.02

[back to top]

Caregiver Global Impression of Change in Attention

Caregiver global impression of change in attention during the double-blind treatment period of ganaxolone compared to placebo. Investigators and caregivers reported improvements in attention, mood, behavior and sleep via investigator narratives (NCT03572933)
Timeframe: End of the double-blind 17 week treatment period

,
InterventionParticipants (Count of Participants)
Very Much Improved - Visit 5 (End of Week 17)Much Improved - Visit 5 (End of Week 17)Minimally Improved - Visit 5 (End of Week 17)No Change - Visit 5 (End of Week 17)Minimally Worse - Visit 5 (End of Week 17)Much Worse - Visit 5 (End of Week 17)Very Much Worse - Visit 5 (End of Week 17)
Ganaxolone122118111
Placebo171423110

[back to top]

Caregiver Global Impression of Change in Seizure Intensity and Duration

Caregiver global impression of change in seizure intensity and duration during the double-blind treatment period of ganaxolone compared to placebo. CGI-C is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. (NCT03572933)
Timeframe: End of the double-blind 17 week treatment period

,
InterventionParticipants (Count of Participants)
Very Much Improved - Visit 5 (End of Week 17)Much Improved - Visit 5 (End of Week 17)Minimally Improved - Visit 5 (End of Week 17)No Change - Visit 5 (End of Week 17)4Minimally Worse - Visit 5 (End of Week 17)Much Worse - Visit 5 (End of Week 17)Very Much Worse - Visit 5 (End of Week 17)
Ganaxolone2151110322
Placebo151121540

[back to top]

Caregiver Global Impression of Change in Target Behavior

Caregiver global impression of change in target behavior during the double-blind treatment period of ganaxolone compared to placebo. Investigators and caregivers reported improvements in attention, mood, behavior and sleep via investigator narratives. (NCT03572933)
Timeframe: End of the double-blind 17 week treatment period

,
InterventionParticipants (Count of Participants)
Very Much Improved - Visit 5 (End of Week 17)Much Improved - Visit 5 (End of Week 17)Minimally Improved - Visit 5 (End of Week 17)No Change - Visit 5 (End of Week 17)Minimally Worse - Visit 5 (End of Week 17)Much Worse - Visit 5 (End of Week 17)Very Much Worse - Visit 5 (End of Week 17)
Ganaxolone042019200
Placebo061422121

[back to top]

Clinical Global Impression of Improvement - Clinician

Clinical global impression of improvement during the double-blind treatment period of ganaxolone compared to placebo (NCT03572933)
Timeframe: [Time Frame: End of the double-blind 17 week treatment period]

,
InterventionParticipants (Count of Participants)
Very Much Improved - Visit 5 (End of Week 17) - ClinicianMuch Improved - Visit 5 (End of Week 17) - ClinicianMinimally Improved - Visit 5 (End of Week 17) - ClinicianNo Change - Visit 5 (End of Week 17) - ClinicianMinimally Worse - Visit 5 (End of Week 17) - ClinicianMuch Worse - Visit 5 (End of Week 17) - ClinicianVery Much Worse - Visit 5 (End of Week 17) - Clinician
Ganaxolone071916231
Placebo071319900

[back to top]

Clinical Global Impression of Improvement - Parent/Caregiver

Clinical global impression of improvement during the double-blind treatment period of ganaxolone compared to placebo. The CGI is rated on a 7-point scale, with the severity of illness scale using a range of responses. (NCT03572933)
Timeframe: End of the double-blind 17 week treatment period

,
InterventionParticipants (Count of Participants)
Very Much Improved - Visit 5 (End of Week 17) - Parent/CaregiverMuch Improved - Visit 5 (End of Week 17) - Parent/CaregiverMinimally Improved - Visit 5 (End of Week 17) - Parent/CaregiverNo Change - Visit 5 (End of Week 17) - Parent/CaregiverMinimally Worse - Visit 5 (End of Week 17) - Parent/CaregiverMuch Worse - Visit 5 (End of Week 17) - Parent/CaregiverVery Much Worse - Visit 5 (End of Week 17) - Parent/Caregiver
Ganaxolone0131714220
Placebo171322410

[back to top]

Percentage of Seizure-free Days for Major Motor Seizure Types

Percentage of Seizure-free Days for Major Motor Seizure types during the double-blind treatment period of ganaxolone compared to placebo. The major motor seizure types include bilateral tonic (sustained motor activity = 3 seconds), generalized tonic-clonic, atonic/drop, bilateral clonic, and focal to bilateral tonic-clonic. (NCT03572933)
Timeframe: End of the double-blind 17 week treatment period

,
Interventionpercent of seizure-free days (Mean)
Baseline17-week-Post-Baseline PhaseArithmetic Change from Baseline
Ganaxolone22.5732.299.62
Placebo30.3236.175.86

[back to top]

Summary of 28-day Seizure Frequency for Subjects in the Biomarker-positive Stratum (Median Percent Change)

Summary of 28-day Seizure Frequency for Seizure Types for Subjects in the Biomarker-positive Stratum through 17 weeks (Median Percent Change) (NCT03865732)
Timeframe: [Time Frame: End of the double-blind 17 week treatment period]

InterventionMedian % Change in Number of Seizures (Median)
Placebo-18.71
Ganaxolone-35.90

[back to top]

Summary of 28-day Seizure Frequency Through 17 Week Post-Baseline Phase (Median Percent Change)

Summary of 28-Day Seizure Frequency for Seizure Types through 17 week Post-Baseline Phase (Median Percent Change) (NCT03865732)
Timeframe: End of the double-blind 17 week treatment period

InterventionMedian % Change in Number of Seizures (Median)
Placebo-23.97
Ganaxolone-61.52

[back to top]

50% Primary Seizure Reduction

Percent of subjects experiencing a greater than or equal to 50% reduction in 28-day primary seizure frequency relative to the 12-week baseline (NCT03865732)
Timeframe: End of the double-blind 17 week treatment period

InterventionParticipants (Count of Participants)
Placebo4
Ganaxolone5

[back to top]

Percentage of Participants Who Are Alive and Free of Respiratory Failure at Day 28

Respiratory failure is defined based on resource utilization, requiring at least one of the following: Endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula (heated, humidified oxygen delivered via reinforced nasal cannula at flow rates >20 liter/minute with fraction of delivered oxygen >=0.5), noninvasive positive pressure ventilation, and extracorporeal membrane oxygenation (ECMO). Percentage of participants who were alive and free of respiratory failure at Day 28 were reported in this outcome measure. (NCT04537806)
Timeframe: Day 28

Interventionpercentage of participants (Number)
Placebo23.1
Brexanolone23.1

[back to top]

Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)

An adverse event (AE) is any untoward medical occurrence in a participant administered with a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom or disease temporally associated with the use of an IP whether or not related to the product. An AE can include any undesirable medical condition, even if no study treatment has been administered. A TEAE is defined as an AE with onset after the start of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study. (NCT04537806)
Timeframe: From first dose of investigational product up to end of study (up to Day 40)

InterventionParticipants (Count of Participants)
Placebo13
Brexanolone14

[back to top]

Number of Participants Who Died Through Day 28

All cause mortality was reported up to Day 28 in this outcome measure. (NCT04537806)
Timeframe: From screening up to Day 28

InterventionParticipants (Count of Participants)
Placebo6
Brexanolone8

[back to top] [back to top]

Percentage of Participants With Medication Error

Medication error was any preventable event that may cause or lead to inappropriate medication use or participant harm while the medication was in the control of the healthcare professional, participant, or consumer. Percentages are rounded off to the nearest single decimal. (NCT05059600)
Timeframe: At screening and during the study (Up to Day 3)

Interventionpercentage of participants (Number)
At ScreeningDuring the Study (Up to Day 3)
ZULRESSO®28.654.8

[back to top]

Percentage of Participants With At Least One Treatment-Emergent Adverse Event (TEAE) Leading to Dose Interruption/Discontinuation

An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered with a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as an AE with onset after the start of investigational product, or any worsening of a preexisting medical condition/AE with onset after the start of investigational product and throughout the study. Percentages are rounded off to the nearest single decimal. (NCT05059600)
Timeframe: Up to Day 3

Interventionpercentage of participants (Number)
ZULRESSO®7.1

[back to top]

Percentage of Participants With Nonadherence With the Safe-Use Conditions for Administration of ZULRESSO®

"Nonadherence was defined by failure of any of following:~Home infusion provider to train all pharmacy and home healthcare providers (HHPs) in dispensing/administration of ZULRESSO® on risk of excessive sedation/loss of consciousness~HHPs to counsel participants on risk of excessive sedation/loss of consciousness~Deliver ZULRESSO® per protocol~Provide preprogrammed peristaltic pump~HHP:assess excessive sedation every 2 hours in planned nonsleep periods, change infusion bag per protocol, at least one HHP available in participant's home for the duration of infusion~Fall protocol in place~Monitor participants with pulse oximeter~Stop infusion when participant is primary caregiver of dependents and/or identification of excessive sedation/loss of consciousness/hypoxic episode~Caution participants post-infusion against engaging in hazardous activities requiring mental alertness~Complete AE of special interest/Serious AE form~Infusion resumed after hypoxia episode" (NCT05059600)
Timeframe: Up to Day 3

Interventionpercentage of participants (Number)
ZULRESSO®76.19

[back to top]

Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. TEAE was defined as an AE with onset after the start of investigational product, or any worsening of a preexisting medical condition/AE with onset after the start of investigational product and throughout the study. Percentages are rounded off to nearest single decimal. (NCT05059600)
Timeframe: Up to Day 3

Interventionpercentage of participants (Number)
ZULRESSO®42.9

[back to top]